Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.
Real Time Conference Coverage : 2026 Mid-Atlantic Capital Conference; November 10, 2026 Philadelphia PA
Reporter: Stephen J. Williams, Ph.D.
Mid-Atlantic Capital Conference
November 9 & 10, 2026
Philadelphia, PA | Presented by PACT
“Cap Con” is one of the largest venture capital conferences on the East Coast — a dynamic platform where innovation meets investment. For over 30 years, the conference has connected emerging growth companies, investors, advisors, and corporate leaders from across the region.
The conference culminates in the Lion’s Den — our version of Shark Tank — where real dollars are invested and real deals are made in front of the room.
Agenda
Tuesday, November 10th 2026
2026 Mid-Atlantic Capital Conference – Pennsylvania Convention Center – 1101 Arch St. Philadelphia, PA 19107
Corporate Innovation Panel Track
10:20 AM – 11:00 AM
201 ABC
Navigating the AI Future: Where Will Value Be Created and Destroyed?
Envision potential future AI scenarios and their implication over the next 3-5 years. It’s a whole new world. AI is reshaping not only what companies build, but what a company can look like. This interactive session will challenge attendees to explore three possible AI Future Scenarios covering shifts in technology, economics, regulation, and societal response to AI as well as the implications for future enterprises from established companies transforming with AI to AI-natives companies disrupting existing markets with a fraction of the employees.
Through scenario discussions and audience polling, investors, founders, and corporate leaders will consider where durable value will exist, what will remain uniquely human, and how these shifts should change the way we invest and innovate.
10:20 AM
204 A
Featured Company Presentations Round 1
Healthcare & Life Sciences
SynchNeuro
Carenostics
Moberg Analytics, Inc.
Polygon Health Analytics LLC
Mind and Match
10:20 AM
204 B
Featured Company Presentations Round 1
Growth Stage
DermaSensor Inc.
Endomedix, Inc.
Meduloc
BLUEWAVE Technologies
Chromatan Inc
10:20 AM
204 C
Featured Company Presentations Round 1
Technology
Raptor Defense Company
Serpent Robotics
BleedIo, Tech
TechNovaTime
Alive3D
11:15 AM – 11:55 AM
201 ABC
Beyond the Pilot: Building AI That Actually Delivers
As organizations gain a clearer understanding of AI’s potential, the focus is shifting toward how these technologies can be thoughtfully adopted and applied to create measurable business value. This session will explore what it takes to move AI, agents, and agentic systems from experimentation into production, where organizations are seeing real ROI, and how leaders can distinguish transformative applications from expensive experimentation.
how can AI be made relevant at scale? How do we move from the pilot AI to a scaled up AI solution
CGI moderates the panel of Jefferson Health, Haleon, and TransAmerica
Abhijit Singh: people were not trusting the new technology; the biggest takeaway he had after initiating pilots was that reengineering the solution was an issue because they had to do AI audits but it tooks time to see which pilots failed, especially in health care; Abhijit agrees with Dean on the pain points that it is even more crucial in healthcare; what is problem trying to solve as experts are needed, a general agentic would not be good enough to give value to healthcare industry; Mark from Haleon agrees with this synopsis
Mark Manning: Consumer healthcare company; they had lots of pilot projects started; they experimented with multiple ideas but had issues with measuring success; the AI platform only good as what it has access to; AI was not giving the depth of answers; they need more relevant agentic AI; he calls the results ‘shallow’
Dean Holland: TransAmerica decided to make their own platform which they call Agentic and seen an acceleration by building their own platform than using an LLM from others like OpenAI; at first they have been having problems with the outcomes; they see an issue with a need for DOMAIN EXPERTISE, it appears to be a pain point in the industry
Question: how are you changing operations in digital teams to produce most value? Mark says their teams are now focused on specific goals so they remain focused on outcomes. How are they partnering with the hyperscalers? Abjihit: There are lots of decision makers in a hospital so multiple teams evaluate adopting any solutions from partners or hyperscalers: for example radiology imaging has acute shortage of radiologists so can they leverage AI to improve radiology workflows;
Question: What comes next and what have you learned from pilots?: Mark; agentic commerce (who do they talk to), should they partner with people or companies; Dean: we are going back to beginning and starting to put projects on hold, they are revisiting their AI strategy (customer engagement and operations will be main focus) and they are needing that deep domain expertise; Jefferson is mainly focused on workflow optimization, however they do see potential to increase physicians interaction time with patients; Jefferson believes in changing entire workflow not just piecemeal solutions to individual problems or time-consuming tasks
TransAmerica wants to work closer with the Anthropics and OpenAI but it is imperative to work with internal teams
question from audience on partnering: Abhijit says AI is actually making partnering harder; Mark agrees that it takes months for internal teams approval to establish a partnership
11:15 AM
204 A
Featured Company Presentations Round 2
Healthcare & Life Sciences
Little One Nutrition Co
Nospharma
Prolifagen, Inc.
BioCurie
CTIBIOTECH USA
11:15 AM
204 B
Featured Company Presentations Round 2
Growth Stage
Mussel Polymers Inc
Setex Technologies
Antithesis Foods
BioFluff Inc
Persevere Therapeutics
11:15 AM
204 C
Featured Company Presentations Round 2
Technology
Phyll
Seedless
Syntropiq Inc.
GreenIRR Inc.
Value Unlimited Inc DBA OnPoint
12:30 PM
Ballroom A/B
Keynote Fireside Chat: Building a Championship Culture with Jay Wright
What does it take to build a winning team and sustain success over time? Join legendary Villanova men’s basketball coach and Naismith Memorial Basketball Hall of Fame inductee Jay Wright for a fireside chat with Stephanie Humphrey on leadership, teamwork, and building a culture of excellence. Drawing from more than two decades leading Villanova, two NCAA national championships, and four Final Four appearances, Wright will share lessons on developing talent, fostering trust, navigating challenges, and creating an environment where individuals and teams can perform at their best. The conversation will explore how the principles behind championship teams can be applied to business, entrepreneurship, and organizational leadership.
1:30 PM – 2:10 PM
201 ABC
Startup × Investor × Corporate: Reinventing the Innovation Model
The traditional playbook for corporate innovation is changing. As AI accelerates ideation, experimentation, lowers barriers to entry, and shortens the time between idea and market, startups, investors, and enterprises are rethinking how they build, buy, partner, and invest. Through real-world examples, this panel will explore how each player can work together to bring innovation to market faster—and what successful partnerships look like in the AI era.
This presentation features a panel with:
Harris Kaplan, Litmys, LLC
Amanda McBride Wilk, Accenture
Ridhard Friedman,Noom
Moderator: Mikchael Bachman, Boomi
What is one thing AI has made less valuable this year?
Amanda: less impressive is flashy demo; need a concrete outputs; domain Knowledge is becoming more and more important; Accenture has the ability to look at large clients data; organizations are not sure where to go with the new technology; most of their successful deals are partnerships; humans are needed for judgement in investment decisions; AI is great at parsing large amounts of information; experts are still needed for judgement calls; AI does not have the experience
Richard: outputs may not be as valuable as the process; why are you doing something is not as important for a builder agentic systems; he says they tested the small models by putting in the LLMs and LLMs are working better for them; context is important; curious why they are stilling feeding LLMs with SLMs
Harris: more valuable faster time to trial; less valuable is increasing using output of AI to do corporate strategy; he talks first hand to physicians and payer and now AI is focusing on the what but lost is the why (like how we change behavior); strategies do not change just the speed at which they can be executed; AI allows companies to assess what is going on quickly and pivot; VC firms need to pivot; AI can be the tool to allow for quick pivot in implementation of strategy
moderator: there will be changes in focus of AI in 2027-28; he has been hearing a lot about outcome based pricing; people are wondering how do you value to metric you are using to make the outcome based pricing; with deal making, Accenture would rather partner than invest and create value of the startup; Noom always looks at the platform and how platform increases value; Most of panel thinks there will be a lot less IPOs in 2027 except in niche areas
1:50 PM
204 A
Featured Company Presentations Round 3
Healthcare & Life Sciences
Dialysis-X, Inc.
Earable Intelligence
TOPAS Solutions, Inc.
Vivifi Medical Inc
Ozie
1:50 PM
204 B
Featured Company Presentations Round 3
Growth Stage
Burro
Raise Robotics, Inc.
Deepwave
Tiami Networks Inc
Transcendap
1:50 PM
204 C
Featured Company Presentations Round 3
Technology
BOSS Controls Inc
BUCKSTOP
CoStream Technologies, Inc.
Dunya Analytics
NanoSepex
2:30 PM – 3:00 PM
201 ABC
Building Advantage in the AI Era with Philip Moyer: Where Will the Next Generation of Value Be Created?
As AI becomes embedded across industries, access to powerful models alone won’t create a lasting competitive advantage. The next wave of opportunity will come from what companies build around them—the proprietary data, industry context, tools, workflows, and feedback loops that turn AI capabilities into differentiated products and measurable value.
In this fireside conversation, Philip Moyer of McGraw Hill will explore where value is being created across the emerging AI stack and what that means for startups, investors, and established companies. Drawing from his experience across the technology industry and now leading within a legacy organization undergoing its own transformation, Moyer will discuss how companies can identify opportunities for differentiation, build stronger data and context with every interaction, and create advantages that become more valuable over time.
The conversation will also examine what young companies should be building today, how established organizations can modernize their operating models, and where the next generation of enduring AI businesses may emerge as the technology continues to evolve.
Moderator: Frederic Miskawi
Where is the next value coming from?
Philip Moyer:
started out at Microsoft in this Philadelphia area. The last mile of any technology is the hardest part. At Mcgraw Hill he has been over the educational spectrum listening to customers (grade school, high school. medical school) The era of Large models will end. In his day AOL was the big player but it all will end. They are encoding all these learning objectives during education (about 30,000 into ontologies). LLMs don’t have the contextual ontology (memory).
Mcgraw Hill has over 1 million curriculums they serve… They want universities to use agentic models as they will help protect copyrights.
most of the clouds like AWS built on open source and
digital moat: 1. speed to market 2. trust (through partnerships) 3. context (move at speed)
McGraw Hill most is built on trust. Education market is 7 trillion market… higher than IT market
disruption only happens when you respect the industry.. respect teachers
show the data and outcomes to everyone (all stakeholders)
pace is also a moat for them: getting the pace of rollout of innovation is important
AI moves from answering questions to making goals. AI can’t make goals now so it is important for human integration to make the goals and let agentic perform the workflows
The tables turn as corporate leaders take the stage to pitch their biggest business and technology challenges to the room. Instead of hearing what startups want to sell, founders and investors will hear directly from enterprises about the problems they are actively trying to solve, where they are looking for innovation, and what they need from potential partners.
The session creates a live marketplace for collaboration: giving startups insight into real enterprise demand; investors visibility into emerging opportunities; and corporations access to new ideas and potential solutions.
4:00 PM – 5:15 PM
201 ABC
Lion’s Den
The conference culminates in the Lion’s Den — our version of Shark Tank — where real dollars are invested and real deals are made in front of the room. Watch innovation meet opportunity as the most impressive start-ups from the day take the stage to pitch their businesses before a panel of investors.
Each company will share how much capital it is seeking and the equity it is offering in return, while investors ask tough questions, evaluate the opportunity, and determine whether to make an investment. More than a competition, Lion’s Den offers an unfiltered look at what it takes to secure investment. Expect bold ideas, candid feedback, and an exciting glimpse into the future of healthcare, technology, and innovation.
Meeting Synopsis
This importance conference brought together three groups of stakeholders in corporate AI adoption: AI engineers, AI corporate strategists and consultants, and investors in AI. There were multiple insights in discussions with these three groups including the long time it takes for any one entity, be it a hospital or a healthcare company, to adopt AI strategy into their workflows. It was apparent that AI is generally being adopted to decrease workflow time and increase efficiency rather than use in discovery. For instance, Jefferson Health mentioned they have to go through teams of physicians and healthcare workers along with IT people to see if any agentic AI can be integrated into their workflows, like radiology. This takes months of strategy meetings before a partnership or deal is made. I did find it interesting that a beta test among patients is not included. Another theme with the investors and consulting firms was they would rather do partnerships and pay for that instead of one off deals. They had mentioned that there will be a dearth of IPOs in the next year 2027. Many of the panelists mentioned it is easy to make agents but the real question is WHY instead of what function does it serve. They were careful of AI costs as well and some eluded to a sort of Blockchain system to contain AI costs. Finally some had mentioned about the last mile for the technology will be the hardest phase for AI. They had mentioned that although these large systems had been built out there is a severe lack of context which only experts in a field can offer. The consulting firms are actively recruiting such experts with domain Knowledge as well as the engineers see this as a pain point in their organizations (the lack of domain expertise).
Tweet Collection
<blockquote class=”twitter-tweet”><p lang=”en” dir=”ltr”>Live coverage from Mid-Atlantic Capital Conference: @MHEducation New CEO Philip Moyer. We are developing multiple agentic #AI to assist teachers on classrooms; a $7 trillion market @PhilaPACT @Pharma_BI @AVIVA1950</p>— Stephen J Williams (@StephenJWillia2) <a href=”https://x.com/StephenJWillia2/status/2120268273526640931?ref_src=twsrc%5Etfw”>November 10, 2026</a></blockquote> <script async src=”https://platform.x.com/widgets.js” charset=”utf-8″></script>
Stephen J Williams
@StephenJWillia2
·
Live coverage from Mid-Atlantic Capital Conference:
Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma
Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD
Updated on 11/29/2025
The Voice of Stephen J. Williams, PhD
Since the formation of the LPBI group in 2012, we have set as a goal to digitally curate and ontologize the biomedical literature. These aspects of our mission, although not understandable to most at that time of our inception, was at the forefront of many academic efforts which became the springboard and initial conceptualization of today’s large language models. In select universities like University of Illinois, University of Delaware, and the Technion, academics and researchers at Microsoft and Google, were laying the framework for a semantic web, or Web 3.0. Another company at the forefront of this idea was a company springing forth from Mathematica, Wolfram Research. This idea for a semantic web would entail the processes of curation, digitization, and ontology creation. Their belief, such as ours, was a precursor and much needed key to the puzzle of moving language from machine learning algorithms to the generative transformers used by artificial intelligence.
However as most efforts in this genre focused on general language, our efforts at LPBI Group were focused on the biomedical field, as we understood, from 2012, that the biomedical literature was unique, and so a unique strategy had to be developed to semantically understand biomedical text, even though at the time of 2012 GPTs were not even a concept. However the potential for doing biomedical text analysis was there, and LPBI Group responded by developing a methodology of scientific curation which involved a multimodal strategy to curate, digitize, and ontologize biomedical findings and text.
It was about at the time of 2012 that other groups, mainly focused of drug development applications (for example at University of Indiana) recognized that new computational power of machine learning algorthims could be useful in analyzing complex biological questions. Please see our Synthetic Biology in Drug Discovery section of our Journal for more information on this. For instance, an early adopter of this strategy, a company called Data2Discovery, one of the earliest AI for drug discovery startups, stated
We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented. We have had some dramatic successes, but we are just starting to discover the impact that data, knowledge graphs, AI and machine learning can together have on drug discovery.
We need all the expertise of academics, consortia, AI companies and pharma to make his happen, and it’s going to require some serious investment, and a big change of thinking. But the opportunity to get drug discovery out of the death spiral and framed for data-driven success is too important to pass up.
However the LPBI Group was cognizant of these changes occuring and pivoted to the developing natural language processing arena as well as ideas for the developing Blockchain technology. This was more of a natural progression for the LPBI Group than a pivot (please read here).
This would be our Vision 2.0, to make biomedical text amenable for Natural Language Processing. We utilized a few strategies in this regard, partnering with a company who was developing NLP for biomedical text analysis, and developing in house machine learning and NLP methods using the Wolfram language environment. Our focus on structuring biomedical text (versus the highly structured genomics and omics data found in many omics related databanks) was prescient for the time. As NLP and machine learning efforts realized, biomedical text needs to have a structure much like genes, proteins and other molecular databases had been organized. Therefore it was realized that structured data was imperative for efficient NLP analysis, a crux for the new GPT which was being developed (and in this mind still is a crux for current GPT and LLM models when it comes to biomedical text analysis).
Our strategy using our scientific curation methodology (as described below in links form our founder Dr. Aviva Lev-Ari, was proven to be highly efficient and amenable to NLP analysis, as a pilot with an NLP company noticed. Most of the data they were using was unstructured and their first step involved annotation and structuring the text, as we had already performed for years. This was critical as our text was able to pull out more concepts, relationships, in a faster time than NLP on sources such as PubMed available text. We had also developed our own in house algorithms for NLP on our material, which is shown in some of our book offerrings and individual articles.
However with the advent of GPT it was thought all this was unnecessary. However this idea that our strategy was outdated or irrelevent in the era of GPT was wholly incorrect to the advocates of a sole GPT strategy to analyze biomedical text and data. It is now understood that structure is needed as some of biomedical-centric GPT projects would find out, such as BioGPT. We have many articles which attest to the lack of accuracy and efficiency of these GPT architectures (seen here). These include failure rates in many areas of healthcare and biomedicine by sole reliance on GPT,
It was realized by many in the biomedical arena, especially those involved in NLP efforts, that there was much value in the semantic web 3.0 idea, and this was readily picked up by those spearheading effort to incorporate knowledge graphs with the new generative AI or GPT technology. We have shown a clear example our scientific methodology of curation with ontology has better inference when combined with knowledge graphs and GPT than reliance on GPT alone
This update was performed by the following methods:
A. GPT 5 Text analysis and Reasoning
B. Insertion of Knowledge Graph on topic Curation of Genomic Analysis from Non Small Cell Lung Cancer Studies from Nodus Labs using InfraNodus software
C. Domain Knowledge Expert evaluation of the Update outcomes
This article has the following Structure:
Part A: Introduction to LLM, Knowledge Graph software InfraNodus, ChatGPT5 and Background Information on curated material for Test Case
Part B: InfraNodus Analysis of manual curation and Knowledge Graph Creation
Part C: Chat GPT 5 Analysis of Manually Curated Material
Part D: Curation entitled Multiple Lung Cancer Genomic Projects Suggest New Targets, Research Directions for Non-Small Cell Lung Cancer originally published on 09/05/2014
Results of Article Update with GPT 5
1. GPT5 alone was not able to understand the goal of the article, namely to determine knowledge gaps in a particular research area involving 5 genomic studies on lung cancer patients
2. GPT5 alone was not able to group concepts or comonalities between biological pathways unless supplied with a manually curated list of KEGG pathways from a list of mutated genes. However this precluded any effect that fusion proteins had on the analysis and so GPT5 would only concentrate on mutated genes commonly found in literature
3. GPT was not able to access some of the open Access databases like NCBI Gene Ontology database
Results of Article Update with KnowledgeGraph presentation to GPT 5
4. As the Knowledge Graph understood the importance of fusion proteins and transversions, the knowledgegraph augmented the GPT analysis and so enriched the known pathways as well as could correctly identify the less represented pathways in the knowledge graph
5. This led to the identification of many novel signaling pathways not identified in the original analysis, and was able to perform this task with ease and speed
6. GPT with InfraNodus Analysis was able to propose pertinent questions for future research (the goal of the original curation) such as:
How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?
How does the intersection of mutational patterns from smoking influence pathway activation in NSCLC, and can identifying these interactions improve targeted therapy development?
Novelty in comparison to Original article published on 09/05/2014
7. it appears that manual curation is necessary to assist in the building of relevant knowledge graphs in the biomedical fields to augment generative AI analysis
8. by itself, generative AI is not optimized for inference of higher concepts from biomedical text, and therefore, at this point, requires the input from human curators developing domain-specific knowledge graphs
9. The combination of ChatGPT5 and Knowledge graphs of this manually curated biomedical text added a further layer of complexity of gaps of knowledge not seen in the original curations including the need to study noncanonical signaling pathways like WNT and Hedgehog in smoker versus nonsmoker cohorts of lung cancer patients
The Voice of Aviva Lev-Ari, PhD, RN
LPBI Group’s Portfolio of Digital IP Assets as Proprietary Training Data Corpus for AI in Medicine, in Life Sciences, in Pharmaceutical and in Health Care Applications
LPBI Group is offering transfer of ownership, in full, a privately held, multimodal healthcare training corpus leveraging propriety unique data set curated by domain experts and mapped to a living ontology for GenAI creating defensibility.
The Portfolio of IP spans:
6,250+ articles (~2.5MM views),
48 e‑books (EN/ES) (+152,000 page downloads),
100+ e‑Proceedings with +50 Tweet collections,
7,500+ biological images with expert context, and
300+ Audio podcasts on Life Sciences breakthroughs.
Each asset (Use Case: Scientific Article) has timestamps, author/role labels, crosslinks, and view histories.
Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.
Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small Language Models or Large Language Models.
Strategic acquirers in Big Pharma of Vertical AI startups (i.e., LPBI Group) with data‑moat strategies
Pharma strategics Acquire LPBI’s end‑to‑end, rights‑clean healthcare knowledge base to accelerate R&D, medical affairs, and safety. Ideal for and with acceleration of R&D, medical affairs, and safety. Emphasize compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA Metadata export plus full text/media transfer for rapid onboarding. Full acquisition only.
Subject: Buy the moat: full acquisition of expert healthcare corpus with clean rights
We’re selling the entire asset: a privately held, multimodal healthcare corpus with centralized training rights and an exportable ontology, validated on gene–disease–drug extraction. It’s ingest‑ready and transfers cleanly via account control plus a metadata export. If owning differentiated data is critical for your agent or workflow, we can provide a diligence preview under NDA.
compliant internal copilots and evidence synthesis enabled by expert curation and living ontology. Close with rapid onboarding under NDA
Five Examples of Domain-aware for model implementation for Small Language Models – English Edition & Spanish Edition
Series A: Cardiovascular Diseases ($515) – Six Volumes
The electronic books are collections of curated articles in biomedical science. The electronic Tables of Contents (eTOCs) of each volume was designed by a senior editor with expertise in the subjects covered in that volume. The curations use as sources published research findings in peer-reviewed scientific journals together with expert added interpretations.
The e-books are designed to make the latest research in the Five Bilingual BioMed e-Series – 37 volumes accessible to practicing health care professionals. These five e-Series cover the following medical specialties:
Cardiovascular diseases and therapies,
Genomics,
Cancer etiology and oncological therapies,
Immunology, and
Patient-centered precision medicine.
The material in these volumes can greatly enhance medical education and provide a resource for continued updating and education for health care professionals. In addition to the 37 e-books, LPBI has published more than 6,000 articles in its online scientific journal “PharmaceuticalIntelligence.com”, which has received 2.5 million views since its launch in 4/2012, Top articles had more than 18,000 views.
The Portfolio is:
rights‑clean,
expert‑curated healthcare corpus
mapped to a living Ontology,
already packaged for immediate model ingestion and
suitable for safe pre-training, evals, and fine‑tuning.
If healthcare domain data is on your roadmap, this is a rare, defensible asset worth a preview.
LPBI Group is offering transfer of ownership, in full, a privately held, multimodal healthcare training corpus leveraging propriety unique data set curated by domain experts and mapped to a living ontology for GenAI creating defensibility. It spans 6,250+ articles (~2.5MM views), 48 e‑books (EN/ES) (+151,000 page downloads), 100+ e‑proceedings with +50 tweet collections, 7,500+ biological images with expert context, and 300+ Audio podcasts on Life Sciences breakthroughs. Each asset has timestamps, author/role labels, crosslinks, and view histories. Rights are centrally assigned with explicit model‑training data by domain-aware for model implementation for Small LMs or LLMs. Metadata export exists; full text and media transfer via WordPress/Amazon account control for immediate ingestion.
For Recognitions and a DETAILED BIO by Perplexity.ai and Gemini 2.5 Pro (experimental), see
“Show Thinking” by AI Deep Research: The AI-generated Biography Description of Aviva Lev-Ari, PhD, RN, Founder of PharmaceuticalIntelligence.com by Perplexity.ai and by Google’s Gemini 2.5 Pro (experimental)
Pfizer, a global pharmaceutical leader, has integrated artificial intelligence (AI) and machine learning (ML) across its operations to accelerate drug discovery, enhance clinical trials, improve manufacturing, and drive patient-centric innovations. These efforts aim to reduce development timelines, boost efficiency, and address challenges like rare disease detection. As of late 2025, Pfizer’s AI strategy emphasizes internal expertise, cloud-based tools (primarily with AWS), and cross-industry collaborations, with a focus on multimodal data analysis and generative AI. Below is a breakdown of key initiatives, drawn from recent developments.
1. Pfizer AI Cloud Transformation (PACT) Program Launched in 2021 with AWS, PACT is a prototyping accelerator for AI/ML applications in lab, clinical manufacturing, and supply chain efforts. It has pursued 14 projects, with five now in production. Key outcomes include:
Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
55% reduction in infrastructure costs through cloud optimization.
Exploration of virtual/augmented reality for training, with rapid prototyping to test feasibility. This program fosters “fail-fast” innovation, enabling quick iteration on ideas like AI-driven predictive modeling.
2. Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D, cutting years off traditional timelines (e.g., from 8–10 years to months for certain candidates).
COVID-19 Initiatives: AI optimized molecular searches for PAXLOVID (oral antiviral), enabling intravenous-to-oral pivots. During vaccine development, the Safety Data Quality (SDQ) tool—a custom AI for clinical trial data management—saved a full month of analysis via the Breakthrough Change Accelerator sandbox.
Precision Medicine and Subpopulation Identification: Advanced ML (classical and deep learning) analyzes molecular datasets from trials to predict patient responses, informing trial design, first-in-human studies, and oncology/inflammatory disease targeting. This has doubled clinical success rates to ~20% (vs. industry 7–10%).
ML Research Hub: Pfizer’s Cambridge, MA-based Biomedical Data Science group builds internal talent for AI in genome sciences, predicting disease outcomes and treatment efficacy using techniques from tech giants like Google.
3. Clinical Trials and Regulatory Efficiency AI automates content creation across the drug lifecycle, from lab data to regulatory docs and patient booklets, ensuring quality and speed.
Predictive Regulatory Tools: ML models forecast regulator queries, proactively addressing safety concerns to build trust and shorten approvals.
Decentralized Trials: The “Clinical Trial Anywhere” model uses AI to integrate remote data (e.g., home health visits), improving recruitment/retention and generating real-world evidence.
Inventory and Supply Chain: AI predicts vaccine storage issues, pioneered during COVID distribution.
4. Disease Detection and Diagnostics
ATTR-CM Initiative: Through the ASPIRE collaboration (with Amyloidosis Research Consortium), AI analyzes EHRs, ECGs, and echocardiograms to detect transthyretin amyloid cardiomyopathy earlier, targeting underdiagnosed heart failure cases.
Rare Diseases: ML models identify symptoms in large datasets, mapping the immune system for better predictions.
5. Generative AI and Operational Tools
Charlie Platform: Rolled out in 2024 for marketing, this gen AI tool (named after co-founder Charles Pfizer) generates compliant content like emails, presentations, and medical article drafts. Trained on approved product data, it streamlines physician targeting and customer insights.
Scientific Data Cloud: AWS-powered centralization of data/ML capabilities, enabling faster research and treating 1.3 billion patients in 2022. It supports gen AI via Amazon SageMaker/Bedrock for manufacturing efficiency.
Global Health Grants: Through the Pfizer Foundation’s AI Learning Lab, funding supports AI for equitable healthcare access, e.g., biometric tools for community care.
6. Partnerships and Education
Collaborations: With AWS for cloud AI; IMI Big Picture for a 3M-sample disease database; IIT Madras for the 2025 AIPM Symposium on AI in pharma (focusing on drug discovery and precision medicine).
Talent and Events: Hosting webinars on AI in manufacturing (e.g., predictive maintenance, regulatory submissions) and engaging leaders like Dr. Subha Madhavan on AI for biomedical data integration.
Strategic Focus: $500M R&D reinvestment by 2026 targets AI for productivity, part of $7.7B cost savings. Emphasis on ethical AI, diverse datasets, and competing with global biotech advances (e.g., China’s AI in CRISPR).
Pfizer’s approach balances operational efficiency with transformative R&D, positioning AI as a core enabler rather than a standalone focus. Ongoing investments, like cloud migrations saving $47M annually and reducing CO2 emissions, underscore sustainability. For the latest, monitor Pfizer’s investor updates or events like AWS re:Invent.
Responsiveness to Big Pharma AI Initiatives by LPBI Group’s Digital IP Portfolio:
Scientific articles
e‑Books in Medicine
e‑Proceedings,
Biological images
Podcasts
AI Initiative at Big Pharma
i.e., Pfizer
Composed @Grok
LPBI Group’s Digital IP Asset:
Journal articles
N = 6,250
Composed by Aviva Lev-Ari
Generative AI tools
that save scientists up to 16,000 hours annually in literature searches and data analysis.
Generative AI tools searching LPBI’s Proprietary data in addition to Public Domain data sources
Journal ONTOLOGY used to optimize context classification selected for search
Drug Discovery and Development Acceleration
Pfizer uses AI, supercomputing, and ML to streamline R&D timelines
– Run prompts by category of research on the following three dyads
– Run ML across categories of research for these three dyads
-Gene-disease
-Disease-drug
-Gene-drug
Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management
Curation competences:
content creation across the drug lifecycle, from lab data to regulatory docs
Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases
Heart Failure Diagnosis by Early detection of transthyretin amyloid cardiomyopathy
– Journal published ~30 curations by Dr. Larry on this subject ATTR-CM
– Run NLP on this Corpus
Rare diseases:
Journal published 560 articles on Rare diseases
– Run ML on this Corpus
Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker /Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care
Content generated in the Journal can become “generated compliant content” if run on the Charlie Platform.
– For REUSE content in context
Entire Corpus of 9 Giga bytes can be ingested to Pfizer Foundation’s AI Learning Lab
– Run prompts against it
– Journal’s Content to be used for Internal staff expertise development
– Journal’s Content for Leadership development
Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on AI in Manufacturing
The Journal had published 547 articles in Precision Medicine
The Journal had published 1,114 articles in Drug Discovery
The Journal had published 701 articles in Drug Delivery
The Journal had published 3,615 articles on subject matter “Disease”
The Journal had published 738 articles on Biomedical topics
The Journal had published 425 articles on Artificial Intelligence (AI)
Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR
The Journal had published 432 articles on CRISPR
Productivity derived from Journal’s content:
– As a result of the fact that ~70% of the Journal’s articles are curations written by Domain Knowledge Experts subjectively expressing theirs clinical interpretations of basic and primary research – the productivity of the knowledge workers at any Big Pharma would increase vastly.
– If Grok and Claude would run on LPBI Group’s Digital IP Corpus, a scientific revolution will emerge
– It is not combinatorics applied to molecules with 98% futile results!!!
it is the IQ of Gifted HUMANS, of domain knowledge experts generating content using individual CREATIVITY no Quantum or Super Intelligence which is not in existence, YET.
– Foundation Models in Healthcare depends on the OUTPUT of the human creative mind. AI takes keyword (classic search) and concepts (semantic search) and run frequency of occurrence and predict the nest word, one word after the next one.
@@@@@@@
AI Initiative at Big Pharma
i.e., Pfizer
LPBI Group’s Digital IP Asset:
e-Books
Domain-aware Editorials and Curations
Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
The electronic Table of Contents of every e-book is a CONCEPTUAL MASTER PIECE of one unique occurrence in Nature generated by the Editor, or the Editors that had
– Commissioned articles for the e-Book
– Had selected articles from collections of Categories of Research created by domain knowledge experts
– Had reviewed the TOTALITY of the Journal’s Ontology and found new concept to cover in the e-Book not originally planned
Had incorporated Highlights of Lectures given at 100 Conferences LPBI Group’s Dr. Lev-Ari and Dr. Willians had cover in Real Real, by invitation, only as PRESS.
– The vision of the Editor-in-Chief of the BioMed e-Series reflects the BIG PICTURE of Patient care delivery.
– UC, Berkeley PhD’83
– Knowledge student and Knowledge worker, 10/1970 to Present
– Conceptual pioneer of 26 algorithms in Decision Science of Operations Management decision support systems
– 2005 to Present in the Healthcare field.
– 2005-2012: Clinical Nurse Manager in Post-acute SNF settings and Long-term Acute care Hospital Supervisor – had developed a unique view on Diagnosis, Therapeutics and Patient care delivery
– The BioMed e-Series is the EPITOM of human CREATIVITY in Healthcare an OPUS MAGNUM created by collaboration of top Scientists, Physicians and MD/PhDs
– The 48 e-Books Published by LPBI Group – represent the ONLY one Publisher on Amazon.com with +151,000 pages downloaded since the 1st e-book published on 6/2013 and since Pay-per-View was launched by Amazon.com in 2016.
Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines
Two volumes on the BioMed e-Series were subjected to Medical Text Analysis with AI, ML, Natural Language Processing (NLP).
– Cancer, Volume 1 (In English, part of the Spanish Edition, Series C)
– Genomics, Volume 2 (In English, part of the Spanish Edition, Series B)
– GPT capabilities are warranted to attempt to subject to ML Analytics every book of the MUTUALLY EXCLUSIVE 48 URLs provided by Amazon.com to LPBI Group, the Publisher.
– 5 URLs for 5 Bundles in The English Edition: Series A,B,C,D,E – English Edition
– All books in each series – 5 Corpuses for domain-aware Small Language Model in English
– All books in each series – 5 Corpuses for domain-aware Small Language Model in Spanish
– 5 URLs for 5 Bundles in The Spanish Edition: Series A,B,C,D,E –Spanish Edition
Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management
Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases
– No one had attempted ML on every book, only two books were analyzed by ML.
– No one had attempted ML on all the Volumes in any of the 5 Series.
– No one had attempted ML on all the 48 books
– WHEN that will be done – a REVOLUTION on Disease Detection and Diagnostics will be seen for the first time because the totality of these 48 books represent the Brains of Human Experts
Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care
Add the content of all the Books to Charlie Platform
Partnerships and Education
Collaborations: IMI Big Picture for 3M – sample disease database
AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
Webinars of AI for biomedical data integration
Webinard on Ai in Manufacturing
e-Books are the SOURCE for Education
– Offer the books as Partnership sustenance
Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR
URLs for the English-language Edition by e-Series:
In these conferences the Frontier of Science was presented, ofter BEFORE publication findings were revealed. These Proceedings are the ONLY written record of the events. They are privately-held, now for the first time available for Transfer of Ownership
The Tweet Collection are QUOTES of speakers on record. NOT ELSEWHERE available by name of speaker and affiliation
Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management
Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases
Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care
Ingest to Charlie Platform ALL e-Proceedings of ALL Conferences
Apply GPT:
Training Data:
– One conference at a time
– All Conference on ONE subject matter, i.e., Immunotherapy, Oncolytic Virus Immunotherapy, Immune Oncology
Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on Ai in Manufacturing
Use Past Conference Agendas to build Future Conference Agendas
Use Speakers Lists to invite speakers/consultants to your events
Use topics covered in Conferences for Employee training & and in-house Leadership development
Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR
Having access to +100 e-Proceedings vs Not having access to this resource is a make or break in fine-tuning Corporate Branding: All your competitors attended and had sent Speakers
LPBI Group’s e-Proceedings is the only record in one URL
@@@@@@
AI Initiative at Big Pharmas
i.e., Pfizer
LPBI Group’s Digital IP Asset:
Biological Images selected by Experts embedded in original Text (Prior Art)
Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines
Gallery of ~8,000 Biological images and captions is a Treasure TROVE for scientific article writing, Presentation preparations. This Media Gallery is an Art collection of top Scholars in Medicine and Biology
Clinical Trials and Regulatory Efficiency AI:
-Predictive Regulatory Tools
-Decentralize Trials
-inventory management
Disease Detection and Diagnostics:
– ATTR-CM Initiative
– Rare diseases
Gallery of ~8,000 Biological images and captions is a Treasure TROVE for Disease Detection and Diagnostics
Generative AI and Operational Tools:
– Charlie Platform
– Scientific Data Cloud AWS powered ML on centralized data
– Amazon’s SageMaker/Bedrock for Manufacturing efficiency
– Global Health Grants:
Pfizer Foundation’s AI Learning Lab for equitable access to care and tools for community care
Ingest into Charlie Platform the Media Gallery for generation of Medical article drafts
Partnerships and Education
– Collaborations: IMI Big Picture for 3M – sample disease database
– AI in Pharma AIPM Symposium: Drug discovery and Precision Medicine
– Webinars of AI for biomedical data integration
– Webinar on Ai in Manufacturing
Strategic Focus:
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR
@@@@@@
AI Initiative at Big Pharma
i.e., Pfizer
LPBI Group’s Digital IP Asset:
Library of Audio and Video Podcasts
N = +300
Generative AI tools that save scientists up to 16,000 hours annually in literature searches and data analysis.
Drug Discovery and Development Acceleration Pfizer uses AI, supercomputing, and ML to streamline R&D timelines
Review ALL SCIENTIFIC BREAKTHROUGHS
Two criteria for Classifications used by Prof. Marcus W. Feldman and by Dr. Stephen J. Williams to generate the two classifications
– $500M R&D reinvestment by 2026 targets AI for Productivity
– Part of $7.7B cost savings
– Ethical AI, diverse DBs
– Global biotech advances: China’s AI in CRISPR
Dr. Lev-Ari Prompted @Grok on 11/18/2025:
AI-Driven Cost Savings in Big Pharma
@Grok responded:
AI-Driven Cost Savings in Big PharmaArtificial intelligence (AI) applications across the pharmaceutical value chain—particularly in drug discovery, clinical trials, and operations—have the potential to generate substantial savings for major pharmaceutical companies (often referred to as “Big Pharma”). Based on recent industry reports and analyses from 2024-2025, these savings vary by application but could collectively reach tens of billions annually by the late 2020s. Projections indicate AI could add up to 11% in value relative to revenue for biopharma firms over the next five years through productivity gains and cost reductions. Below, I break down the estimated savings levels by key areas, drawing from credible sources like McKinsey, Deloitte, IQVIA, and others.
Clinical Trials
Annual Industry-Wide Savings: By 2030, AI integration into 60-70% of clinical trials could save the pharmaceutical industry $20-30 billion per year through faster timelines, better patient matching, and reduced administrative costs.
Per-Trial Cost Reduction: AI can cut trial costs by up to 70% and shorten durations by 80%, enabling quicker regulatory submissions (40% faster) with 50% improved cost efficiency. For example, AstraZeneca reported up to 25% shorter trial durations in cancer drug studies using AI for dose optimization and biomarker identification.
Specific Efficiency Gains: Feasibility surveys can see 90% time reductions using AI/ML tools.
Drug Discovery and Development
R&D Cost Drop: AI could reduce drug discovery costs by up to 40%, with overall development timelines shrinking from 5 years to 12-18 months (an 80% cut in some cases). From discovery to preclinical candidate stage, timelines can decrease by up to 50%.
Total Clinical Development Savings: Projected at $25 billion across the sector, driven by AI-accelerated pipelines.
Operations and Broader Impacts
Value Relative to Revenue: Biopharma AI investments may yield up to 11% additional value (e.g., via cost efficiencies and revenue growth) over five years. For related medtech segments, savings could hit 12% of total revenue within 2-3 years.
Operating Profits Boost: By 2030, AI could add $254 billion in annual operating profits industry-wide through productivity jumps (e.g., 50-100% in quality control) and lead time reductions (60-70%).
Time-to-Market: Up to 10% faster overall, with production KPIs improving revenue by 25%.
These estimates assume scaled adoption, with global AI spending in pharma rising from ~$3 billion in 2025 to $22-25 billion by 2027-2030. Challenges like high initial costs and data infrastructure may temper short-term gains, but early adopters (e.g., Pfizer, Novartis) are already seeing ROI. For context, the global pharma market is projected at $1.6 trillion by 2025, so even modest percentages translate to billions in savings. If you need details on a specific AI use case or company, let me know!
Overview of Pfizer and Key CompetitorsPfizer is one of the world’s largest pharmaceutical companies, with a strong focus on innovative medicines and vaccines. Its primary competitors include Merck & Co., Johnson & Johnson (J&J), Roche, Novartis, and now AstraZeneca, based on revenue leadership and market overlap in areas like oncology, immunology, and vaccines. These companies dominate the global pharmaceutical industry, which is projected to reach $1.21 trillion in revenue by 2025. Below, I compare them across size (measured by 2024 revenue and employees), market share (approximate global pharma share based on 2024 revenues), product lines (key therapeutic areas and top products), and investments in AI technologies. Data reflects the latest available figures as of late 2025.
Here are the same comparisons with more concise tables (2024 data, latest available as of Nov 2025):
Size (2024 Revenue & Employees)
Company
Revenue (USD B)
Employees
Merck & Co.
64.2
70,000
Pfizer
63.6
88,000
Roche
~58.3
103,000
J&J (pharma only)
57.8
138,000
AstraZeneca
54.1
94,300
Novartis
~50.0
76,000
Approx. Global Pharma Market Share
Company
Share %
Merck & Co.
4.3
Pfizer
4.2
J&J / Roche
3.9
AstraZeneca
3.6
Novartis
3.3
Key Product Lines & Top Sellers (2024 revenue, USD B)
Company
Main Areas
Top Products (revenue)
Pfizer
Vaccines, cardiology, oncology
Eliquis (7.3), Prevnar (6.4), Vyndaqel (5.4)
Merck & Co.
Oncology, vaccines
Keytruda (25.0), Gardasil (8.6)
J&J
Immunology, oncology
Stelara (10.9), Darzalex (9.7)
AstraZeneca
Oncology, CVRM, respiratory
Farxiga (7.7), Tagrisso (6.6), Enhertu (4.0)
Roche
Oncology, neurology, hemophilia
Ocrevus (5.7), Hemlibra (4.0)
Novartis
Cardiology, immunology
Entresto (6.6), Cosentyx (5.2)
AI Investment Snapshot (2025)
Company
AI Highlights (2025)
Scale/Impact
Pfizer
AI cuts discovery from years → 30 days; heavy partnerships
Leader in adoption
AstraZeneca
Evinova AI trials unit; $2.5B AI Beijing hub; 12k+ staff upskilled
Very aggressive (>85% productivity gain)
Merck & Co.
Gen-AI for protocols; 20+ AI “blockbusters” in pipeline
>$1.2B spend
J&J
900+ AI projects → $500M savings; surgical AI training
Broad internal rollout
Roche
AI diagnostics + drug discovery; $55M Manifold Bio deal
Searched for “(“AI” OR “artificial intelligence”) (“biotech” OR “biotechnology”) startup since:2025-01-01″
10 results
Show All (2)
AI in Biotech Startups:
2025 LandscapeArtificial Intelligence (AI) is revolutionizing biotech startups by accelerating drug discovery, optimizing clinical trials, and enabling personalized medicine. In 2025, AI applications like generative models for molecule design and predictive analytics for protein structures are slashing R&D timelines from years to months, reducing costs by up to 30%, and boosting success rates. The sector blends biology’s complexity with AI’s data-crunching power, drawing massive VC interest amid ethical debates on gene editing and biosecurity.Key Trends
Explosive Funding Growth: U.S. healthcare VC hit $23B in 2024, with ~30% ($5.6B) targeting AI-biotech—nearly triple 2023 levels. Biopharma startups raised $24.2B across 568 deals, up from $10.1B in 2023. Q3 2025 saw $97B global VC (up 38% YoY), half to AI firms. Mega-rounds ($100M+) surged, focusing on drug discovery and rare diseases.
Market Expansion: Global AI-biotech market: $4.6B in 2025, projected to $11.4B by 2030 (20% CAGR). Biotech overall to $5.85T by 2034 (13.6% CAGR), driven by AI in gene editing, microbiome therapeutics, and automation.
Compute Demands: Biotech AI requires massive GPUs; Nvidia’s AI sales hit $41.1B in one 2025 quarter (56% YoY). Startups lean on cloud partnerships (e.g., AWS-Recursion) or in-house clusters, with hyperscalers eyeing $3-4T infrastructure by 2030.
Regional Hotspots: North America leads (42% share) via FDA support and hubs like Boston/SF; Europe grows via funding/regulatory advances; Asia (e.g., China) via collaborations.
Challenges & Ethics: Selective funding favors clinically validated firms; rising M&A (big pharma acquiring AI startups); ethical scrutiny on AI gene editing (e.g., CRISPR enhancements).
Notable Startups & Recent Funding
Here’s a snapshot of standout AI-biotech startups, highlighting innovations and 2024-2025 funding:
Startup
Focus Area
Key Innovation
Recent Funding (2025)
Insilico Medicine
Drug Discovery
Generative AI for novel molecules
$100M+ Series D (ongoing)
Recursion Pharmaceuticals
Phenomics & Drug Repurposing
AI mapping diseases via cell images
$50M partnership w/ Nvidia
Absci Corp.
Protein Design
AI-generated antibodies/proteins
$20M from AMD (Jan 2025)
TandemAI
Drug Discovery
ML for molecular simulation
$22M Series A extension
Red Queen Bio
Biosecurity
AI for pathogen detection/design
$15M Seed led by OpenAI
Antiverse
Antibody Design
AI predicting antibody structures
Deal w/ Nxera Pharma (2024)
Deep Genomics
Genomics
AI extracting insights from DNA data
VC round undisclosed
Aizen Therapeutics
Molecule Generation
Proprietary AI engines for trials
Early-stage VC
These firms exemplify AI’s shift from hype to pipeline impact—e.g., Insilico’s AI-discovered drug entered Phase II trials in record time.Emerging ApplicationsAI’s top uses in biotech startups:
Drug Discovery: ML predicts drug-target interactions (e.g., AlphaFold-inspired tools cut screening costs 70%).
Genomics & Diagnostics: AI analyzes vast datasets for rare variants, powering precision oncology.
2025 signals a “quality over quantity” pivot: Investors prioritize AI startups with real-world data and partnerships (e.g., Y Combinator, Google for Startups). M&A will rise as big pharma (Pfizer, Merck) snaps up talent. Yet, compute shortages and regs (e.g., FDA AI guidelines) pose hurdles. For founders, blending AI with wet-lab validation is key to unlocking the next wave of breakthroughs—potentially curing diseases once deemed untreatable. If you’re building or investing, focus on
Key Products and Focus AreasPfizer’s portfolio spans immunology, oncology, cardiology, endocrinology, neurology, and vaccines. In 2024, its top revenue generators included:
Eliquis (apixaban, blood thinner): $7.3 billion (11% of total revenue).
Prevnar family (pneumococcal vaccines): $6.4 billion (10%).
Paxlovid (COVID-19 antiviral): $5.7 billion (9%).
Vyndaqel (tafamidis, for rare heart disease): $5.4 billion (8%).
Comirnaty (COVID-19 vaccine): $5.3 billion (8%).
Ibrance (palbociclib, breast cancer drug): $4.3 billion (6%).
The company is investing heavily in AI-driven drug discovery (e.g., 2024 partnerships with NVIDIA and Saama) and next-gen therapies like RSV vaccines, gene therapies for muscular dystrophy, and oral GLP-1 drugs for obesity/diabetes. Challenges include patent expirations (e.g., Eliquis in 2026-2028) and biosimilar competition, but Pfizer’s diversified pipeline positions it for mid-single-digit growth in 2025.Pfizer’s Main CompetitorsPfizer operates in a highly competitive $1.5 trillion global pharma market, where rivals vie for dominance in oncology, vaccines, immunology, and emerging areas like obesity and gene therapy. Its primary competitors are fellow “Big Pharma” giants, often overlapping in therapeutic areas. Based on revenue, market share, and direct product rivalries, here are the top ones (ranked roughly by 2024 revenue for context):
Competitor
Headquarters
2024 Revenue (Pharma Segment)
Key Strengths & Overlaps with Pfizer
Notable Products
Johnson & Johnson (J&J)
New Brunswick, NJ, USA
$88.8 billion (total; pharma ~$57.8 billion)
Diversified (pharma, devices, consumer); strong in oncology, immunology, vaccines. Competes directly in blood thinners and cancer therapies.
Oncology and immunology; Opdivo directly competes with Pfizer’s Bavencio in checkpoint inhibitors.
Opdivo (immunotherapy), Eliquis (co-developed with Pfizer, but BMS handles ex-US).
Sanofi S.A.
Paris, France
~$46 billion
Vaccines and rare diseases; Dupixent challenges in immunology; rivals Prevnar in pneumococcal vaccines.
Dupixent (atopic dermatitis), Lantus (diabetes).
These competitors collectively hold over 50% of the global pharma market share. Emerging threats include biotech upstarts like Moderna (mRNA vaccines, directly rivaling Comirnaty) and generics firms like Teva (eroding post-patent revenues). In 2025, competition intensifies in obesity (Novo/Lilly lead) and oncology (Merck/Roche dominate), with tariffs and pricing pressures (e.g., US executive orders) affecting all.Pfizer’s edge comes from its scale and partnerships (e.g., BioNTech for mRNA), but it must navigate revenue dips from COVID fade-out and biosimilars. For 2025 projections, analysts expect 6-9% growth across the sector, with Pfizer targeting modest gains through oncology expansions. If you’d like deeper dives on specific rivals, financials, or products, let me know!
2d • 2 days ago • Visible to anyone on or off LinkedIn
AI in Pharma: From Tool to Value Creator 🚀
Over the past 5 years, pharma’s AI footprint has expanded rapidly and the investment trends tell a clear story.
💡 ~60% of collaborations and acquisitions now focus on TargetDiscovery and Validation — pharma’s main frontier to shorten early-stage R&D timelines and boost success rates through PrecisionBiology.
⚗️ The second-largest area (~25%) centers on AI-driven DrugDesign and MoleculeOptimization, where algorithms accelerate CandidateSelection, refine molecular properties, and enable NewModalities such as Biologics and CellAndGeneTherapies.
🏆 Among top players, Eli Lilly and Company stands out as the most active investor — making AI a true StrategicCapability, not just another research tool.
The takeaway?
AI isn’t just supporting pharma anymore, it’s reshaping it.
“Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma”
This November 15, 2025, article on PharmaceuticalIntelligence.com (curated by LPBI Group) makes a compelling case for leveraging LPBI’s decade-plus of expert-curated digital IP as a high-fidelity, rights-clean training corpus to supercharge AI-driven innovation in Big Pharma. It contrasts the limitations of generic LLMs (like GPT) with the need for domain-specific, ontologized biomedical data, positioning LPBI’s assets as a “defensible moat” for accelerating R&D in drug discovery, precision medicine, and beyond. The piece blends market analysis of pharma giants with a deep dive into LPBI’s portfolio, emphasizing its multimodal, metadata-rich structure for NLP, knowledge graphs, and fine-tuning SLMs/LLMs.IntroductionThe thesis: In an era where AI investments in pharma (e.g., Eli Lilly’s aggressive funding) focus on slashing R&D timelines by 60%+ in target discovery and 25% in drug design, LPBI’s proprietary corpus—built since 2012 via human curation, digitization, and ontology mapping—offers unmatched authenticity over web-scraped data. It addresses GPT’s biomedical shortcomings (e.g., failing to infer fusion proteins or noncanonical pathways without curated inputs) and highlights LPBI’s foresight in text analysis for generative AI augmentation. A key quote from Data2Discovery: “We are able to improve drug discovery now as well as demonstrating new fast-cycle AI-driven processes that will have a revolutionary impact on drug discovery if fully implemented.”Portfolio OverviewLPBI’s ~9 GB, debt-free, multimodal corpus is privately held, expert-curated (e.g., by Prof. Marcus W. Feldman and Dr. Stephen J. Williams), and ingest-ready for AI pre-training/evaluations. It spans five key asset classes, each with metadata exports, timestamps, crosslinks, and centralized rights for model training:
Asset Class
Description & Size
Unique Value Proposition
I: Scientific Articles
6,250+ articles on PharmaceuticalIntelligence.com (~2.5M views); covers genomics, oncology, immunology, etc.
Live ontology, author/role labels, view histories; enables temporal NLP for trend analysis.
II: e-Books
48 bilingual (English/Spanish) volumes in 5 BioMed e-Series (e.g., Series A: Cardiovascular, 6 vols., $515 total; Series E: Patient-Centered, 4 vols., $274); 151,000+ page downloads; 2,728 articles.
Peer-reviewed, senior-editor TOCs; pay-per-view model proves demand; ideal for entity-relationship extraction.
III: e-Proceedings
100+ from biotech/genomics conferences (2013–2025); +50 tweet collections as speaker quotes with affiliations.
Real-time event curation; captures emerging insights for knowledge graph augmentation.
V: Biological Images
7,500+ images in Digital Art Media Gallery; embedded as prior art in texts.
Expert-contextualized visuals; supports multimodal AI for image-text pairing in diagnostics.
X: Audio Podcasts
300+ interviews with scientific leaders (e.g., Nobel laureates like Jennifer Doudna); classified by themes like CRISPR, mRNA vaccines.
Transcripts + NLP WordClouds; adds auditory/verbal depth for voice-enabled AI copilots.
The portfolio’s “living ontology” allows seamless integration into tools like InfraNodus for concept mapping.AI Training RelevanceUnlike PubMed’s unstructured dumps, LPBI’s assets are pre-annotated for concept extraction (e.g., gene-disease-drug dyads), reducing hallucinations and bias in LLMs. A case study integrates curation with ChatGPT-5: Manual ontology + knowledge graphs uncovered novel WNT/Hedgehog interactions in lung cancer, generating research questions like: “How does the interaction between [[EGFR]] mutations and sex-specific gene alterations, including [[RBM10]], influence treatment outcomes in lung adenocarcinoma?” This hybrid approach outperforms solo GPT, proving the corpus’s role in trustworthy biomedical inference.Applications
Drug Discovery: ML prompts on dyads to mimic Pfizer’s AI (e.g., reducing discovery from years to months); supports biologics/cell therapies.
Precision Medicine: 547 articles for patient subtyping; 3,615 disease-focused pieces for predictive modeling.
Diagnostics & Rare Diseases: 560 rare disease articles + 30 on ATTR-CM for early detection (e.g., via Pfizer’s ASPIRE AI).
Clinical/Regulatory: Streamlines trials, evidence synthesis, and content generation (e.g., via Pfizer’s “Charlie” copilot, saving hours on lit reviews).
Generative Tools: Fine-tune for compliant, domain-aware outputs in medical affairs/safety.
Challenges & Solutions
Data Quality/Bias: Unstructured text leads to GPT errors; solved by expert curation + ontology for accurate, diverse inputs.
Regulatory Compliance: Rights fragmentation; addressed via LPBI’s centralized assignment for NDA-secure licensing.
Scalability: Generic data overload; LPBI’s focused, high-signal corpus enables fast-cycle AI without noise.
Recommendations
Urge Big Pharma (e.g., Pfizer, Merck—table highlights Merck’s $64.2B revenue, Keytruda focus) to acquire the full portfolio for end-to-end knowledge bases, or license under NDA for SLM/LLM training (English/Spanish).
Emphasizes “buy the moat” for competitive edge in 2025’s 6–9% sector growth (obesity/oncology hotspots).
Contact: avivalev-ari@alum.berkeley.edu.
Conclusion
LPBI’s corpus isn’t just data—it’s a “scientific revolution enabler,” blending human creativity with AI for transformative pharma impact. Validated on extraction tasks, it’s primed for partnerships, outshining combinatorial predictions with authentic, curated depth. This article builds on prior LPBI mappings (e.g., our podcast TOC summary), reinforcing the portfolio’s strategic fit for AI.
For deeper analysis or related assets, let me know!
The Use of ChatGPT in the World of BioInformatics and Cancer Research and Development of BioGPT by MIT
Curator: Stephen J. Williams, Ph.D.
Chatbots are being used in multiple interdisciplanary areas in research and medicine and so it was a natural progression to incorporate artificial intelligence (AI), natural language processing (NLP), and chatbot technology like ChatGPT into bioinformatic analysis.
“In domains like informatics, management and marketing, media and communication science, languages and philosophy, psychology and sociology, engineering, design, and human-computer interaction, the fast expanding body of chatbot study is clearly interdisciplinary.
The field of bioinformatics is a natural fit for incorporting this technology. The curated information below shows some use examples of this technology in bioinformatics related to cancer research.
How ChatGPT can be used in bioinformatics research?
ChatGPT is a variant of the GPT (Generative Pre-trained Transformer) language model that was designed to generate human-like text in a conversational setting. It is not directly related to bioinformatics, which is the field of study that deals with the storage, retrieval, and analysis of biological data, particularly in the context of genetics and genomics. However, ChatGPT could potentially be used in a bioinformatics context as a tool for generating natural language descriptions of genetic or genomic data, or for generating responses to queries about such data.
For example, a researcher could use ChatGPT to generate descriptions of genetic variants or gene expression patterns based on input data. This could be useful for generating summaries of results for reports or papers, or for generating explanations of complex concepts for non-expert audiences. ChatGPT could also be used to generate responses to queries about genetic or genomic data, such as “What is the function of gene X?” or “What are the potential consequences of variant Y?”
It’s worth noting that ChatGPT is just one of many tools and techniques that can be used in bioinformatics, and it is unlikely to be the most suitable or effective option in every situation. There are many specialized tools and resources available for working with biological data, and it is often necessary to use a combination of these tools to fully analyze and understand the data.
Generating descriptions of genetic or genomic data: ChatGPT could be used to generate natural language descriptions of genetic or genomic data based on input data. For example, suppose a researcher has a dataset containing information about gene expression levels in different tissues. The researcher could use ChatGPT to generate a description of the data, such as:
“Gene X is highly expressed in the liver and kidney, with moderate expression in the brain and heart. Gene Y, on the other hand, shows low expression in all tissues except for the lung, where it is highly expressed.”
Thereby ChatGPT, at its simplest level, could be used to ask general questions like “What is the function of gene product X?” and a ChatGPT could give a reasonable response without the scientist having to browse through even highly curated databases lie GeneCards or UniProt or GenBank. Or even “What are potential interactors of Gene X, validated by yeast two hybrid?” without even going to the curated InterActome databases or using expensive software like Genie.
Summarizing results: ChatGPT could be used to generate summaries of results from genetic or genomic studies. For example, a researcher might use ChatGPT to generate a summary of a study that found a association between a particular genetic variant and a particular disease. The summary might look something like this:
“Our study found that individuals with the variant form of gene X are more likely to develop disease Y. Further analysis revealed that this variant is associated with changes in gene expression that may contribute to the development of the disease.”
It’s worth noting that ChatGPT is just one tool that could potentially be used in these types of applications, and it is likely to be most effective when used in combination with other bioinformatics tools and resources. For example, a researcher might use ChatGPT to generate a summary of results, but would also need to use other tools to analyze the data and confirm the findings.
ChatGPT is a variant of the GPT (Generative Pre-training Transformer) language model that is designed for open-domain conversation. It is not specifically designed for generating descriptions of genetic variants or gene expression patterns, but it can potentially be used for this purpose if you provide it with a sufficient amount of relevant training data and fine-tune it appropriately.
To use ChatGPT to generate descriptions of genetic variants or gene expression patterns, you would first need to obtain a large dataset of examples of descriptions of genetic variants or gene expression patterns. You could use this dataset to fine-tune the ChatGPT model on the task of generating descriptions of genetic variants or gene expression patterns.
Here’s an example of how you might use ChatGPT to generate a description of a genetic variant:
First, you would need to pre-process your dataset of descriptions of genetic variants to prepare it for use with ChatGPT. This might involve splitting the descriptions into individual sentences or phrases, and encoding them using a suitable natural language processing (NLP) library or tool.
Next, you would need to fine-tune the ChatGPT model on the task of generating descriptions of genetic variants. This could involve using a tool like Hugging Face’s Transformers library to load the ChatGPT model and your pre-processed dataset, and then training the model on the task of generating descriptions of genetic variants using an appropriate optimization algorithm.
Once the model has been fine-tuned, you can use it to generate descriptions of genetic variants by providing it with a prompt or seed text and asking it to generate a response. For example, you might provide the model with the prompt “Generate a description of a genetic variant associated with increased risk of breast cancer,” and ask it to generate a response. The model should then generate a description of a genetic variant that is associated with increased risk of breast cancer.
It’s worth noting that generating high-quality descriptions of genetic variants or gene expression patterns is a challenging task, and it may be difficult to achieve good results using a language model like ChatGPT without a large amount of relevant training data and careful fine-tuning.
To train a language model like chatGPT to extract information about specific genes or diseases from research papers, you would need to follow these steps:
Gather a large dataset of research papers that contain information about the specific genes or diseases you are interested in. This dataset should be diverse and representative of the types of papers you want the model to be able to extract information from.
Preprocess the text data in the research papers by tokenizing the text and creating a vocabulary. You may also want to consider lemmatizing or stemming the text to reduce the dimensionality of the dataset.
Train the language model on the preprocessed text data. You may want to fine-tune a pre-trained model such as chatGPT on your specific dataset, or you can train a new model from scratch.
ChatGPT could also be useful for sequence analysis
A few examples of sequence analysis a ChatGPT could be useful include:
Protein structure
Identifying functional regions of a protein
Predicting protein-protein interactions
Identifying protein homologs
Generating Protein alignments
All this could be done without having access to UNIX servers or proprietary software or knowing GCG coding
ChatGPT in biomedical research
There are several potential ways that ChatGPT or other natural language processing (NLP) models could be applied in biomedical research:
Text summarization: ChatGPT or other NLP models could be used to summarize large amounts of text, such as research papers or clinical notes, in order to extract key information and insights more quickly.
Data extraction: ChatGPT or other NLP models could be used to extract structured data from unstructured text sources, such as research papers or clinical notes. For example, the model could be trained to extract information about specific genes or diseases from research papers, and then used to create a database of this information for further analysis.
Literature review: ChatGPT or other NLP models could be used to assist with literature review tasks, such as identifying relevant papers, extracting key information from papers, or summarizing the main findings of a group of papers.
Predictive modeling: ChatGPT or other NLP models could be used to build predictive models based on large amounts of text data, such as electronic health records or research papers. For example, the model could be trained to predict the likelihood of a patient developing a particular disease based on their medical history and other factors.
It’s worth noting that while NLP models like ChatGPT have the potential to be useful tools in biomedical research, they are only as good as the data they are trained on, and it is important to carefully evaluate the quality and reliability of any results generated by these models.
ChatGPT in text mining of biomedical data
ChatGPT could potentially be used for text mining in the biomedical field in a number of ways. Here are a few examples:
Extracting information from scientific papers: ChatGPT could be trained on a large dataset of scientific papers in the biomedical field, and then used to extract specific pieces of information from these papers, such as the names of compounds, their structures, and their potential uses.
Generating summaries of scientific papers: ChatGPT could be used to generate concise summaries of scientific papers in the biomedical field, highlighting the main findings and implications of the research.
Identifying trends and patterns in scientific literature: ChatGPT could be used to analyze large datasets of scientific papers in the biomedical field and identify trends and patterns in the data, such as emerging areas of research or common themes among different papers.
Generating questions for further research: ChatGPT could be used to suggest questions for further research in the biomedical field based on existing scientific literature, by identifying gaps in current knowledge or areas where further investigation is needed.
Generating hypotheses for scientific experiments: ChatGPT could be used to generate hypotheses for scientific experiments in the biomedical field based on existing scientific literature and data, by identifying potential relationships or associations that could be tested in future research.
PLEASE WATCH VIDEO
In this video, a bioinformatician describes the ways he uses ChatGPT to increase his productivity in writing bioinformatic code and conducting bioinformatic analyses.
He describes a series of uses of ChatGPT in his day to day work as a bioinformatian:
Using ChatGPT as a search engine: He finds more useful and relevant search results than a standard Google or Yahoo search. This saves time as one does not have to pour through multiple pages to find information. However, a caveat is ChatGPT does NOT return sources, as highlighted in previous postings on this page. This feature of ChatGPT is probably why Microsoft bought OpenAI in order to incorporate ChatGPT in their Bing search engine, as well as Office Suite programs
ChatGPT to help with coding projects: Bioinformaticians will spend multiple hours searching for and altering open access available code in order to run certain function like determining the G/C content of DNA (although there are many UNIX based code that has already been established for these purposes). One can use ChatGPT to find such a code and then assist in debugging that code for any flaws
ChatGPT to document and add coding comments: When writing code it is useful to add comments periodically to assist other users to determine how the code works and also how the program flow works as well, including returned variables.
One of the comments was interesting and directed one to use BIOGPT instead of ChatGPT
0:54 oh dear. You cannot use chatgpt like that in Bioinformatics as it is rn without double checking the info from it. You should be using biogpt instead for paper summarisation. ChatGPT goes for human-like responses over precise information recal. It is quite good for debugging though and automating boring awkward scripts
The BioGPT model was proposed in BioGPT: generative pre-trained transformer for biomedical text generation and mining by Renqian Luo, Liai Sun, Yingce Xia, Tao Qin, Sheng Zhang, Hoifung Poon and Tie-Yan Liu. BioGPT is a domain-specific generative pre-trained Transformer language model for biomedical text generation and mining. BioGPT follows the Transformer language model backbone, and is pre-trained on 15M PubMed abstracts from scratch.
The abstract from the paper is the following:
Pre-trained language models have attracted increasing attention in the biomedical domain, inspired by their great success in the general natural language domain. Among the two main branches of pre-trained language models in the general language domain, i.e. BERT (and its variants) and GPT (and its variants), the first one has been extensively studied in the biomedical domain, such as BioBERT and PubMedBERT. While they have achieved great success on a variety of discriminative downstream biomedical tasks, the lack of generation ability constrains their application scope. In this paper, we propose BioGPT, a domain-specific generative Transformer language model pre-trained on large-scale biomedical literature. We evaluate BioGPT on six biomedical natural language processing tasks and demonstrate that our model outperforms previous models on most tasks. Especially, we get 44.98%, 38.42% and 40.76% F1 score on BC5CDR, KD-DTI and DDI end-to-end relation extraction tasks, respectively, and 78.2% accuracy on PubMedQA, creating a new record. Our case study on text generation further demonstrates the advantage of BioGPT on biomedical literature to generate fluent descriptions for biomedical terms.
Tips:
BioGPT is a model with absolute position embeddings so it’s usually advised to pad the inputs on the right rather than the left.
BioGPT was trained with a causal language modeling (CLM) objective and is therefore powerful at predicting the next token in a sequence. Leveraging this feature allows BioGPT to generate syntactically coherent text as it can be observed in the run_generation.py example script.
The model can take the past_key_values (for PyTorch) as input, which is the previously computed key/value attention pairs. Using this (past_key_values or past) value prevents the model from re-computing pre-computed values in the context of text generation. For PyTorch, see past_key_values argument of the BioGptForCausalLM.forward() method for more information on its usage.
This model was contributed by kamalkraj. The original code can be found here.
BioGPT is MIT-licensed. The license applies to the pre-trained models as well.
Contributing
This project welcomes contributions and suggestions. Most contributions require you to agree to a Contributor License Agreement (CLA) declaring that you have the right to, and actually do, grant us the rights to use your contribution. For details, visit https://cla.opensource.microsoft.com.
When you submit a pull request, a CLA bot will automatically determine whether you need to provide a CLA and decorate the PR appropriately (e.g., status check, comment). Simply follow the instructions provided by the bot. You will only need to do this once across all repos using our CLA.
As of right now this does not seem Open Access, however a sign up is required!
We provide our pre-trained BioGPT model checkpoints along with fine-tuned checkpoints for downstream tasks, available both through URL download as well as through the Hugging Face 🤗 Hub.
Luo R, Sun L, Xia Y, Qin T, Zhang S, Poon H, Liu TY.Brief Bioinform. 2022 Nov 19;23(6):bbac409. doi: 10.1093/bib/bbac409.PMID: 36156661
We evaluate BioGPT on six biomedical natural language processing tasks and demonstrate that our model outperforms previous models on most tasks. …Our case study on text generation further demonstrates the advantage of BioGPT on biomedical literature to generate fl …
Here they show the advantages of BioGPT over BioBERT and ChatGPT in an example of text extraction and question answer
Table 7. Example of generated text
Input Model Text
Bicalutamide GPT-2 Bicalutamide, a synthetic bicalutamide derivative, was found to increase the cellular proliferation
of C. elegans cells. This effect was not observed with the other synthetic bicalutamide derivatives. This is in line with our previous work which showed that bicalutamide increases the proliferation of C. elegans cells but not in the presence of synthetic bicalutamide.
BioGPT Bicalutamide (Casodex) is an androgen receptor (AR) antagonist approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on or are ineligible for docetaxel chemotherapy, as well as for the treatment of early-stage prostate cancer in men who have not progressed on or are ineligible for docetaxel chemotherapy, as well as for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) in men who have not progressed on or are ineligible for docetaxel chemotherapy.
Janus kinase 3 (JAK-3) GPT-2 Janus kinase 3 (JAK-3) mediates the conversion of glucose to glycogen in skeletal muscle. The
increase in glucose uptake by skeletal muscle is believed to be associated with a reduction in muscle protein breakdown and with the release of ketone bodies, which contribute to the metabolism of glucose.
BioGPT Janus kinase 3 (JAK-3) is a member of the Janus kinase (JAK) family of non-receptor tyrosine kinases and plays an important role in the regulation of cell proliferation, differentiation, survival, migration and angiogenesis.
Apricitabine GPT-2 Apricitabine, duloxetine and citalopram) were investigated in patients with a history of
treatment-resistant depression (n = 10). We found that treatment with the three drugs significantly decreased depressive symptoms, but not depressive symptoms over the next 12 weeks. We conclude that antidepressant drugs that reduce depressive symptoms and reduce depressive symptoms over time may be beneficial in patients with recurrent depression.
BioGPT Apricitabine is an oral prodrug of 5-aza-2 ’-deoxycytidine (5-aza-CdR), a DNA methyltransferase (DNMT) inhibitor, which has been approved by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in combination with low-dose cytarabine (Ara-C) and granulocyte colony-stimulating factor (G-CSF) for patients with intermediate-2 or high-risk MDS or AML.
Xylazine GPT-2 Xylazine, the ‘active ingredient’ in ‘bath salts’ (see above) has been linked to numerous deaths,
including those of former University of California, Berkeley, professor Andrew Anglin, who posted
a video of himself having a bath filled with it.
BioGPT Xylazine is an alpha 2-adrenoceptor agonist which has been used as a sedative and analgesic in veterinary medicine for many years, but its effects on the cardiovascular system have not been extensively studied in the dog, and its effects on the central nervous system (CNS) have not been well characterized in the dog, despite the fact that xylazine has been widely used as a sedative and analgesic in veterinary medicine for more than 30 years.
Psoralen GPT-2 Psoralen, the city of the spiritualist, and had been given to him by God, who wished to show him
the way of salvation, and to draw him back to the true life of Christ, and to bring him into communion with his fellow-man.
BioGPT Psoralen photochemotherapy (PUVA) is a well-established treatment for psoriasis, but its use is limited by the risk of skin cancer, particularly squamous cell carcinoma (SCC) of the head and neck (H & N), which is the most common site of skin cancer in the United States (US)
CP-673451 GPT-2 CP-673451) and 4-5-6-3-1-2-3-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-
BioGPT CP-673451 is a potent, selective, and orally active inhibitor of human neutrophil elastase (HNE) and human cathepsin G (CatG) with in vitro and in vivo anti-inflammatory activity in a variety of animal models of inflammation and in a model of acute lung injury (ALI) in the rat induced by intratracheal instillation of lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha), a model of acute lung injury (ALI) in which neutrophils play an important role.
BIIB-021 GPT-2 BIIB-021A-2-1.pdf. Wright, C. (2002). ‘The War on Terror: A Legal Theory of Terrorist Attacks,’ in
L.E.R. Wright, S.R. Warrick and J.H. Rothman (Eds.), The War on Terror: Essays in Honor of Michael T. Klare (New York: Oxford University Press), 143-57.
BioGPT BIIB-021 is a novel, orally active, non-peptide bradykinin B2 receptor antagonist with potent and long-lasting anti-inflammatory activity in animal models of acute and chronic inflammation and in a rat model of adjuvant-induced arthritis (AIA), an animal model of rheumatoid arthritis (RA) and in a rat model of collagen-induced arthritis (CIA), an animal model of collagen-induced arthritis (CIA), in which arthritis is induced by immunization with bovine type II collagen (CII).
Huang L, Lin J, Li X, Song L, Zheng Z, Wong KC.Brief Bioinform. 2022 Jan 17;23(1):bbab451. doi: 10.1093/bib/bbab451.PMID: 34791012
The rapid growth in literature accumulates diverse and yet comprehensive biomedical knowledge hidden to be mined such as drug interactions. However, it is difficult to extract the heterogeneous knowledge to retrieve or even discover the latest and novel knowledge in an efficient manner. To address such a problem, we propose EGFI for extracting and consolidating drug interactions from large-scale medical literature text data. Specifically, EGFI consists of two parts: classification and generation. In the classification part, EGFI encompasses the language model BioBERT which has been comprehensively pretrained on biomedical corpus. In particular, we propose the multihead self-attention mechanism and packed BiGRU to fuse multiple semantic information for rigorous context modeling. In the generation part, EGFI utilizes another pretrained language model BioGPT-2 where the generation sentences are selected based on filtering rules.
Results: We evaluated the classification part on ‘DDIs 2013’ dataset and ‘DTIs’ dataset, achieving the F1 scores of 0.842 and 0.720 respectively. Moreover, we applied the classification part to distinguish high-quality generated sentences and verified with the existing growth truth to confirm the filtered sentences. The generated sentences that are not recorded in DrugBank and DDIs 2013 dataset demonstrated the potential of EGFI to identify novel drug relationships.
Jin Q, Yang Y, Chen Q, Lu Z.ArXiv. 2023 May 16:arXiv:2304.09667v3. Preprint.PMID: 37131884 Free PMC article.
While large language models (LLMs) have been successfully applied to various tasks, they still face challenges with hallucinations. Augmenting LLMs with domain-specific tools such as database utilities can facilitate easier and more precise access to specialized knowledge. In this paper, we present GeneGPT, a novel method for teaching LLMs to use the Web APIs of the National Center for Biotechnology Information (NCBI) for answering genomics questions. Specifically, we prompt Codex to solve the GeneTuring tests with NCBI Web APIs by in-context learning and an augmented decoding algorithm that can detect and execute API calls. Experimental results show that GeneGPT achieves state-of-the-art performance on eight tasks in the GeneTuring benchmark with an average score of 0.83, largely surpassing retrieval-augmented LLMs such as the new Bing (0.44), biomedical LLMs such as BioMedLM (0.08) and BioGPT (0.04), as well as GPT-3 (0.16) and ChatGPT (0.12). Our further analyses suggest that: (1) API demonstrations have good cross-task generalizability and are more useful than documentations for in-context learning; (2) GeneGPT can generalize to longer chains of API calls and answer multi-hop questions in GeneHop, a novel dataset introduced in this work; (3) Different types of errors are enriched in different tasks, providing valuable insights for future improvements.
PLEASE WATCH THE FOLLOWING VIDEOS ON BIOGPT
This one entitled
Microsoft’s BioGPT Shows Promise as the Best Biomedical NLP
gives a good general description of this new MIT/Microsoft project and its usefullness in scanning 15 million articles on PubMed while returning ChatGPT like answers.
Please note one of the comments which is VERY IMPORTANT
bioGPT is difficult for non-developers to use, and Microsoft researchers seem to default that all users are proficient in Python and ML.
Much like Microsoft Azure it seems this BioGPT is meant for developers who have advanced programming skill. Seems odd then to be paying programmers multiK salaries when one or two Key Opinion Leaders from the medical field might suffice but I would be sure Microsoft will figure this out.
ALSO VIEW VIDEO
This is a talk from Microsoft on BioGPT
Other Relevant Articles on Natural Language Processing in BioInformatics, Healthcare and ChatGPT for Medicine on this Open Access Scientific Journal Include
Infertility is a major reproductive health issue that affects about 12% of women of reproductive age in the United States. Aneuploidy in eggs accounts for a significant proportion of early miscarriage and in vitro fertilization failure. Recent studies have shown that genetic variants in several genes affect chromosome segregation fidelity and predispose women to a higher incidence of egg aneuploidy. However, the exact genetic causes of aneuploid egg production remain unclear, making it difficult to diagnose infertility based on individual genetic variants in mother’s genome. Although, age is a predictive factor for aneuploidy, it is not a highly accurate gauge because aneuploidy rates within individuals of the same age can vary dramatically.
Researchers described a technique combining genomic sequencing with machine-learning methods to predict the possibility a woman will undergo a miscarriage because of egg aneuploidy—a term describing a human egg with an abnormal number of chromosomes. The scientists were able to examine genetic samples of patients using a technique called “whole exome sequencing,” which allowed researchers to home in on the protein coding sections of the vast human genome. Then they created software using machine learning, an aspect of artificial intelligence in which programs can learn and make predictions without following specific instructions. To do so, the researchers developed algorithms and statistical models that analyzed and drew inferences from patterns in the genetic data.
As a result, the scientists were able to create a specific risk score based on a woman’s genome. The scientists also identified three genes—MCM5, FGGY and DDX60L—that when mutated and are highly associated with a risk of producing eggs with aneuploidy. So, the report demonstrated that sequencing data can be mined to predict patients’ aneuploidy risk thus improving clinical diagnosis. The candidate genes and pathways that were identified in the present study are promising targets for future aneuploidy studies. Identifying genetic variations with more predictive power will serve women and their treating clinicians with better information.
Gian M. Volpicelli is a senior writer at WIRED, where he covers cryptocurrency, decentralization, politics, and technology regulation. He received a master’s degree in journalism from City University of London after studying politics and international relations in Rome. He lives in London.
The duo behind Twitter Crypto say NFT profile pics and crypto tipping are just the beginning.
YOU MIGHT HAVE heard of crypto Twitter, the corner of the social network where accounts have Bored Apes as profile pictures, posts are rife with talk of tokens, blockchains, and buying the Bitcoin dip, and Elon Musk is venerated.
Then again, you might have heard of Twitter Crypto, the business unit devoted to developing the social network’s strategy for cryptocurrency, blockchains, and that grab-bag of decentralized technologies falling under the rubric of Web3. The team’s unveiling came in November 2021 via a tweet from the newly hired project lead, Tess Rinearson, a Berlin-based American computer scientist whose career includes stints at blockchain companies such as Tendermint and Interchain.
Rinearson joined Twitter at a crucial moment. Jack Dorsey, the vociferously pro-Bitcoin company CEO, would leave a few weeks later, to be replaced by CTO Parag Agrawal. Agrawal had played an instrumental role in Bluesky, a Twitter-backed project to create a protocol—possibly with blockchain components—to build decentralized social networks.
As crypto went mainstream globally and crypto Twitter burgeoned, the company tried to dominate the space. Under the stewardship of product manager Esther Crawford, in September 2021 Twitter introduced a “tipping” feature that helps creators on Twitter to receive Bitcoin contributions through Lightning—a network for fast Bitcoin payments. In January, Twitter allowed subscribers of Twitter’s premium service, Twitter Blue, to flaunt their NFTs as hexagonal profile pictures, through a partnership with NFT marketplace OpenSea.
Twitter Crypto is just getting started. While Rinearson works with people all across the company, her team is still under 10 people, although more hires are in the pipeline, judging from recent job postings. So it’s worth asking what is next. I caught up over a video call with Rinearson and Crawford to talk about where Twitter Crypto is headed.
The conversation has been edited for clarity and brevity.
WIRED: Let’s start with the basics. Why does Twitter have a crypto unit?
Tess Rinearson: We really see crypto—and what we’re now calling Web3— as something that could be this incredibly powerful tool that would unlock a lot for our users. The whole crypto world is like an internet of money, an internet of value that our users can potentially tap into to create new ways of owning their content, monetizing their content, owning their own identity, and even relating to each other.
One of my goals is to build Twitter’s crypto unit in such a way that it caters to communities that go beyond just that core crypto community. I love the crypto Twitter space, obviously—I’m a very proud member of the crypto community. And at the same time, I recognize that people who are really deep in the crypto space may not relate to concepts, like for instance blockchain’s immutability, in the same way that someone who’s less intensely involved might feel about those things.
So a lot of what we try to think about is, what can we learn from this group of people who are super engaged and really, really, creative? And then, how can we translate some of that stuff into a format or a mechanism or a product that’s a little bit more accessible to people who don’t have that background?
How are you learning from crypto Twitter? Do you just follow a lot of accounts, do you actually talk to them? How does that learning experience play out?
Esther Crawford: It’s a combination. We have an amazing research team that sets up panel interviews and surveys. But we’re also embedded in the community itself and follow a bunch of accounts, sit on Twitter spaces, go to conferences and events, engage with customers in that way. That’s the way the research piece of it works. But we also encounter it as end users: Twitter is the discovery platform today for all things crypto.
One of the things we do differently at Twitter is we build out in the open. And so this means having dialog with customers in real time—designers will take something that is very early-stage and post it as a tweet and then get real-time feedback. They’ll hop into spaces with product managers and engineering managers, talk about it live with real customers, and then incorporate that feedback into the designs and what ultimately we end up launching.
Rinearson: One of the things I wanted to make sure of before I came to Twitter was to know that we would be able to build features in the open and solicit feedback and show rough drafts. And so this is something I asked Parag Agrawal, who’s now the CEO, and was the person who hired me. Pretty early in the job interview process, I said this was going to be really important, and he said, “If you think it’s important to the success of this work, great, do it—thumbs up.” He also shares that openness.
As you said, Tess, you come from crypto. When you were out there, what did you think Twitter was getting right? What did you think Twitter was getting wrong?
Rinearson: I had been a Twitter power user for a really long time. The thing that I saw was a lot of aesthetic alignment between how Twitter exists in the world and the way that crypto exists in the world. Twitter has decentralized user experiences in its DNA. And, this is a bit cheesy, but people use Twitter sometimes in ways that they use a public blockchain, as a public database where everything’s time stamped and people can agree on what happened.
And for most people it’s open, it is there for public conversation. And then obviously it was also the place—a place—where the crypto community really found its footing. I think it’s been a place where an enormous amount of discovery happens, and education and learning for the whole community. I joined when there were some murmurings about Twitter starting to do crypto stuff, mostly stuff Esther had led actually, and I was excited to see where it was going. And then Twitter’s investment in Bluesky also gave me a lot of confidence.
Let’s talk about the two main things you have delivered so far: The crypto tipping feature and NFT pictures. Can you give me just a potted history of how each came about and why?
Crawford: Those are our first set of early explorations, and the reason why we started there was we really wanted to make sure that what we built benefited creators, their audiences, and then all the conversations that are happening on Twitter. For creators in particular, we know that they rely on platforms like Twitter to monetize and earn a living, and not all people are able to use traditional currencies. Not everybody has a traditional banking account setup.
And so we wanted to provide an opportunity for a borderless payment solution, and that’s why we decided to go ahead and use Bitcoin Lightning as our first big integration. One of the reasons we chose Bitcoin Lightning was also because of the low transaction fees. And we have Bitcoin and Ethereum addresses that you can also put in there [on your Twitter “tipping jar”]. We noticed that people were actually adding information about their crypto wallet addresses in their profiles. And so we wanted to make a more seamless experience, so that people could just tip through the platform, so that it felt native.
With NFT profile pictures, the way that came about was, again, looking at user behavior. People were adding NFTs that they owned as avatars, but you didn’t really know whether they owned those NFTs or not. So we decided to go ahead and build out that feature so that one could actually prove ownership.
That’s similar to how other things developed on Twitter, right? The hashtag, or even even the retweet, were initially just things users invented—by adding the # sign, or by pasting other users’ tweets—and then Twitter made that a feature.
Crawford: Yeah, exactly. Many of the best ideas come from watching user behavior on the platform, and then we just productize that.
Rinearson: Sometimes I’ve heard people call that the “help wanted signs,” and like, keeping an eye out for the “help wanted signs” across the platform. The NFT profile picture was a clear example of that.
How do all these things—these two things and possibly other crypto features coming further down the line—really help Twitter’s bottom line?
Crawford:With creator monetization our goal was to help creators get paid, not Twitter. But Twitter takes a really small cut of earnings. For more successful creators, we take a larger percentage. The way we think about this is, it is part of our revenue diversification.
Twitter today is a wholly ad-based business. In the future we imagine Twitter making money from a variety of different product areas. So Twitter Blue is one of those products—you can pay $2.99 a month and you get additional features, such as the NFT profile pictures. We really think that revenue diversification sits across a variety of areas, and creator monetization is one really small component of that.
As you said, these are just early experiments. Where is Twitter Crypto going next? What’s your vision for crypto technology’s role within Twitter?
Rinearson: The real trick here is to find the right parts of Twitter to decentralize, and to not try to decentralize everything at once—or, you know, make every user suddenly responsible for taking care of some private keys or something like that.
We have to find the right ways to open up some access to a decentralized economic layer, or give people ways that they can take their identity with them, without relying on a single centralized service.
We’re really early in these explorations, and even looking at things like Bitcoin tipping or the NFT profile pictures—we view those features as experiments themselves in a lot of ways and learning experiences. We’re learning things about how our users relate to these concepts, what they understand about them, what they find confusing, and what’s most useful to them. We really want to try to use this technology to bring utility to people and you know, not just like, sprinkle a little blockchain on it for the sake of it. So creator monetization is an area that I’m really excited about because I think there’s a really clear path forward. But again, we’re looking beyond that: We’re also looking at using crypto technology in fields like [digital] identity and [digital] ownership space and also figuring out how we can better serve crypto communities on the platform.
Are you going to put Twitter verified users’ blue ticks on a blockchain, then?
[Laughter]
No?
[More laughter]
OK, moving on. How does the kind of work you do dovetail with Bluesky’s plan to create a protocol for a decentralized social media platform? Is there any synergy there?
Rinearson: I have known Jay [Graber], the Bluesky lead, for a long time, and she and I are in pretty close contact. We check in with each other regularly and talk a lot about problems we might have in common that we’ll both need to solve. There’s an overlap looking at things in the identity area, but at the end of the day, it’s a separate project. She’s pretty focused on hiring her team, and they’re very focused on building a prototype of a protocol. That is different from what Esther and I are thinking about, which is like: There are all these blockchain protocols that exist, and we need to figure out how to make them useful and accessible for real people.
And when I say “real people,” I mean that in a sort of tongue-in-cheek contrast to hardcore crypto nerds like me. Jay is thinking much more about building for people who are creating decentralized networks. That is a very different focus area. Beyond that, I would just say it’s too early to say what Bluesky will mean for Twitter as a product. We are in touch, we have aligned values. But at the end of the day—separate teams.
Why is a centralized Silicon Valley company like Twitter the right place to start to bring more decentralization to internet users? Don’t we have just to start from scratch, build a new platform that is already decentralized?
Rinearson: I started in crypto in 2015, and I have a very vivid memory from those years of watching some of my coworkers—crypto engineers—trying to figure out how to secure some of their Bitcoin like before one of the Bitcoin forks [in which the Bitcoin blockchain split, creating new currencies], and they were panicking and freaking out. I thought there was no way that a normal person would be able to handle this in a way that would be safe. And so I was a little bit disillusioned with crypto, especially from a consumer perspective.
And then last year, I started seeing more interest from people whom I’ve known for a long time and weren’t crypto people. They were just starting to perk their heads up and take notice and start creating NFTs or start talking about DAOs. And I thought that that was interesting, that we were coming around a corner, and it might be time to start thinking about what this could mean for people beyond that hardcore crypto group.
And that was when Twitter reached out. You know, I don’t think that just any centralized platform would be able to bring crypto to the masses, so to speak. But I think Twitter has the right stuff. I think you have to meet people where they are with new technologies: find ways to onboard them and bring them along and show them what this might mean for them. make things accessible. And it’s really, really hard to do that with just a protocol. You need to have some kind of community, you need to have some kind of user base, you need to have some kind of platform. And Twitter’s just right there.
I don’t think I would say that a centralized platform is definitely the way to “bring crypto to the masses.” I do think that Twitter is the way to do it.
But why do the masses need crypto right now?
Rinearson: I don’t know that anyone needs crypto, and our goal is not to get everyone into crypto. Let’s be clear about that. But I do think that crypto is a potentially very powerful tool for people. And so I think what we are trying to do is show people how powerful it is and unlock those possibilities. It’s also possible that we create some products and features, where people actually don’t even really know what’s happening under the hood.
Like maybe we’re using crypto as a payment rail or again as an identity layer—users don’t necessarily need to know all of those implementation details. And that’s actually something we come back to a lot: What level of abstraction are we talking about with users? What story are we telling them about what’s happening under the hood? But yeah, I would just like to reiterate that the goal is not to just shovel everyone into crypto. We want to provide value for people.
Do you think there is a case for Twitter to launch its own cryptocurrency— a Twittercoin?
Rinearson: I think there’s a case for a lot of things—honestly, there’s a case for a lot of things. We’re trying to think really, really broadly about it.
Crawford: We’re actively exploring a lot of things. It’s not it’s not something we would be making an announcement about.
Rinearson: I think it is really important to stress that when you say “Twittercoin” you probably have a slightly different idea of what it is than we do. And are we exploring those ideas? Yes, we want to think about all of them. Do we have road maps for them? No. But are we trying to think about things really creatively and be really, really open-minded? Yes. We have this new economic technology that we think could unlock a lot of things for people. And we want to go down a bunch of rabbit holes and see what we come up with.
Gian M. Volpicelli is a senior writer at WIRED, where he covers cryptocurrency, decentralization, politics, and technology regulation. He received a master’s degree in journalism from City University of London after studying politics and international relations in Rome. He lives in London.
Highlighted Text in BLUE, BLACK, GREEN, RED by Aviva Lev-Ari, PhD, RN
In this article, I will list 9 free Harvard courses that you can take to learn data science from scratch. Feel free to skip any of these courses if you already possess knowledge of that subject.
Step 1: Programming
The first step you should take when learning data science is to learn to code. You can choose to do this with your choice of programming language?—?ideally Python or R.
If you’d like to learn R, Harvard offers an introductory R course created specifically for data science learners, called Data Science: R Basics.
This program will take you through R concepts like variables, data types, vector arithmetic, and indexing. You will also learn to wrangle data with libraries like dplyr and create plots to visualize data.
If you prefer Python, you can choose to take CS50’s Introduction to Programming with Python offered for free by Harvard. In this course, you will learn concepts like functions, arguments, variables, data types, conditional statements, loops, objects, methods, and more.
Both programs above are self-paced. However, the Python course is more detailed than the R program, and requires a longer time commitment to complete. Also, the rest of the courses in this roadmap are taught in R, so it might be worth learning R to be able to follow along easily.
Step 2: Data Visualization
Visualization is one of the most powerful techniques with which you can translate your findings in data to another person.
With Harvard’s Data Visualization program, you will learn to build visualizations using the ggplot2 library in R, along with the principles of communicating data-driven insights.
Step 3: Probability
In this course, you will learn essential probability concepts that are fundamental to conducting statistical tests on data. The topics taught include random variables, independence, Monte Carlo simulations, expected values, standard errors, and the Central Limit Theorem.
The concepts above will be introduced with the help of a case study, which means that you will be able to apply everything you learned to an actual real-world dataset.
Step 4: Statistics
After learning probability, you can take this course to learn the fundamentals of statistical inference and modelling.
This program will teach you to define population estimates and margin of errors, introduce you to Bayesian statistics, and provide you with the fundamentals of predictive modeling.
Step 5: Productivity Tools (Optional)
I’ve included this project management course as optional since it isn’t directly related to learning data science. Rather, you will be taught to use Unix/Linux for file management, Github, version control, and creating reports in R.
The ability to do the above will save you a lot of time and help you better manage end-to-end data science projects.
Step 6: Data Pre-Processing
The next course in this list is called Data Wrangling, and will teach you to prepare data and convert it into a format that is easily digestible by machine learning models.
You will learn to import data into R, tidy data, process string data, parse HTML, work with date-time objects, and mine text.
As a data scientist, you often need to extract data that is publicly available on the Internet in the form of a PDF document, HTML webpage, or a Tweet. You will not always be presented with clean, formatted data in a CSV file or Excel sheet.
By the end of this course, you will learn to wrangle and clean data to come up with critical insights from it.
Step 7: Linear Regression
Linear regression is a machine learning technique that is used to model a linear relationship between two or more variables. It can also be used to identify and adjust the effect of confounding variables.
This course will teach you the theory behind linear regression models, how to examine the relationship between two variables, and how confounding variables can be detected and removed before building a machine learning algorithm.
Step 8: Machine Learning
Finally, the course you’ve probably been waiting for! Harvard’s machine learning program will teach you the basics of machine learning, techniques to mitigate overfitting, supervised and unsupervised modelling approaches, and recommendation systems.
Step 9: Capstone Project
After completing all the above courses, you can take Harvard’s data science capstone project, where your skills in data visualization, probability, statistics, data wrangling, data organization, regression, and machine learning will be assessed.
With this final project, you will get the opportunity to put together all the knowledge learnt from the above courses and gain the ability to complete a hands-on data science project from scratch.
Note: All the courses above are available on an online learning platform from edX and can be audited for free. If you want a course certificate, however, you will have to pay for one.
Each of these posts were on the importance of scientific curation of findings within the realm of social media and the Web 2.0; a sub-environment known throughout the scientific communities as Science 2.0, in which expert networks collaborated together to produce massive new corpus of knowledge by sharing their views, insights on peer reviewed scientific findings. And through this new media, this process of curation would, in itself generate new ideas and new directions for research and discovery.
The platform sort of looked like the image below:
This system lied above a platform of the original Science 1.0, made up of all the scientific journals, books, and traditional literature:
In the old Science 1.0 format, scientific dissemination was in the format of hard print journals, and library subscriptions were mandatory (and eventually expensive). Open Access has tried to ameliorate the expense problem.
Previous image source: PeerJ.com
To index the massive and voluminous research and papers beyond the old Dewey Decimal system, a process of curation was mandatory. The dissemination of this was a natural for the new social media however the cost had to be spread out among numerous players. Journals, faced with the high costs of subscriptions and their only way to access this new media as an outlet was to become Open Access, a movement first sparked by journals like PLOS and PeerJ but then begrudingly adopted throughout the landscape. But with any movement or new adoption one gets the Good the Bad and the Ugly (as described in my cited, above, Clive Thompson article). The bad side of Open Access Journals were
costs are still assumed by the individual researcher not by the journals
the arise of the numerous Predatory Journals
Even PeerJ, in their column celebrating an anniversary of a year’s worth of Open Access success stories, lamented the key issues still facing Open Access in practice
which included the cost and the rise of predatory journals.
In essence, Open Access and Science 2.0 sprung full force BEFORE anyone thought of a way to defray the costs
Can Web 3.0 Finally Offer a Way to Right the Issues Facing High Costs of Scientific Publishing?
Web 1.0 and Web 2.0 refer to eras in the history of the Internet as it evolved through various technologies and formats. Web 1.0 refers roughly to the period from 1991 to 2004, where most websites were static webpages, and the vast majority of users were consumers, not producers, of content.[6][7] Web 2.0 is based around the idea of “the web as platform”,[8] and centers on user-created content uploaded to social-networking services, blogs, and wikis, among other services.[9] Web 2.0 is generally considered to have begun around 2004, and continues to the current day.[8][10][4]
The term “Web3”, specifically “Web 3.0”, was coined by Ethereum co-founder Gavin Wood in 2014.[1] In 2020 and 2021, the idea of Web3 gained popularity[citation needed]. Particular interest spiked towards the end of 2021, largely due to interest from cryptocurrency enthusiasts and investments from high-profile technologists and companies.[4][5] Executives from venture capital firm Andreessen Horowitz travelled to Washington, D.C. in October 2021 to lobby for the idea as a potential solution to questions about Internet regulation with which policymakers have been grappling.[11]
Web3 is distinct from Tim Berners-Lee‘s 1999 concept for a semantic web, which has also been called “Web 3.0”.[12] Some writers referring to the decentralized concept usually known as “Web3” have used the terminology “Web 3.0”, leading to some confusion between the two concepts.[2][3] Furthermore, some visions of Web3 also incorporate ideas relating to the semantic web.[13][14]
Web3 revolves around the idea of decentralization, which proponents often contrast with Web 2.0, wherein large amounts of the web’s data and content are centralized in the fairly small group of companies often referred to as Big Tech.[4]
Specific visions for Web3 differ, but all are heavily based in blockchain technologies, such as various cryptocurrencies and non-fungible tokens (NFTs).[4]Bloomberg described Web3 as an idea that “would build financial assets, in the form of tokens, into the inner workings of almost anything you do online”.[15] Some visions are based around the concepts of decentralized autonomous organizations (DAOs).[16]Decentralized finance (DeFi) is another key concept; in it, users exchange currency without bank or government involvement.[4]Self-sovereign identity allows users to identify themselves without relying on an authentication system such as OAuth, in which a trusted party has to be reached in order to assess identity.[17]
Technologists and journalists have described Web3 as a possible solution to concerns about the over-centralization of the web in a few “Big Tech” companies.[4][11] Some have expressed the notion that Web3 could improve data security, scalability, and privacy beyond what is currently possible with Web 2.0 platforms.[14]Bloomberg states that sceptics say the idea “is a long way from proving its use beyond niche applications, many of them tools aimed at crypto traders”.[15]The New York Times reported that several investors are betting $27 billion that Web3 “is the future of the internet”.[18][19]
Some companies, including Reddit and Discord, have explored incorporating Web3 technologies into their platforms in late 2021.[4][20] After heavy user backlash, Discord later announced they had no plans to integrate such technologies.[21] The company’s CEO, Jason Citron, tweeted a screenshot suggesting it might be exploring integrating Web3 into their platform. This led some to cancel their paid subscriptions over their distaste for NFTs, and others expressed concerns that such a change might increase the amount of scams and spam they had already experienced on crypto-related Discord servers.[20] Two days later, Citron tweeted that the company had no plans to integrate Web3 technologies into their platform, and said that it was an internal-only concept that had been developed in a company-wide hackathon.[21]
Some legal scholars quoted by The Conversation have expressed concerns over the difficulty of regulating a decentralized web, which they reported might make it more difficult to prevent cybercrime, online harassment, hate speech, and the dissemination of child abuse images.[13] But, the news website also states that, “[decentralized web] represents the cyber-libertarian views and hopes of the past that the internet can empower ordinary people by breaking down existing power structures.” Some other critics of Web3 see the concept as a part of a cryptocurrency bubble, or as an extension of blockchain-based trends that they see as overhyped or harmful, particularly NFTs.[20] Some critics have raised concerns about the environmental impact of cryptocurrencies and NFTs. Others have expressed beliefs that Web3 and the associated technologies are a pyramid scheme.[5]
Kevin Werbach, author of The Blockchain and the New Architecture of Trust,[22] said that “many so-called ‘web3’ solutions are not as decentralized as they seem, while others have yet to show they are scalable, secure and accessible enough for the mass market”, adding that this “may change, but it’s not a given that all these limitations will be overcome”.[23]
David Gerard, author of Attack of the 50 Foot Blockchain,[24] told The Register that “web3 is a marketing buzzword with no technical meaning. It’s a melange of cryptocurrencies, smart contracts with nigh-magical abilities, and NFTs just because they think they can sell some monkeys to morons”.[25]
Below is an article from MarketWatch.com Distributed Ledger series about the different forms and cryptocurrencies involved
by Frances Yue, Editor of Distributed Ledger, Marketwatch.com
Clayton Gardner, co-CEO of crypto investment management firm Titan, told Distributed Ledger that as crypto embraces broader adoption, he expects more institutions to bypass bitcoin and invest in other blockchains, such as Ethereum, Avalanche, and Terra in 2022. which all boast smart-contract features.
Bitcoin traditionally did not support complex smart contracts, which are computer programs stored on blockchains, though a major upgrade in November might have unlocked more potential.
“Bitcoin was originally seen as a macro speculative asset by many funds and for many it still is,” Gardner said. “If anything solidifies its use case, it’s a store of value. It’s not really used as originally intended, perhaps from a medium of exchange perspective.”
For institutions that are looking for blockchains that can “produce utility and some intrinsic value over time,” they might consider some other smart contract blockchains that have been driving the growth of decentralized finance and web 3.0, the third generation of the Internet, according to Gardner.
“Bitcoin is still one of the most secure blockchains, but I think layer-one, layer-two blockchains beyond Bitcoin, will handle the majority of transactions and activities from NFT (nonfungible tokens) to DeFi,“ Gardner said. “So I think institutions see that and insofar as they want to put capital to work in the coming months, I think that could be where they just pump the capital.”
Decentralized social media?
The price of Decentralized Social, or DeSo, a cryptocurrency powering a blockchain that supports decentralized social media applications, surged roughly 74% to about $164 from $94, after Deso was listed at Coinbase Pro on Monday, before it fell to about $95, according to CoinGecko.
In the eyes of Nader Al-Naji, head of the DeSo foundation, decentralized social media has the potential to be “a lot bigger” than decentralized finance.
“Today there are only a few companies that control most of what we see online,” Al-Naji told Distributed Ledger in an interview. But DeSo is “creating a lot of new ways for creators to make money,” Al-Naji said.
“If you find a creator when they’re small, or an influencer, you can invest in that, and then if they become bigger and more popular, you make money and they make and they get capital early on to produce their creative work,” according to AI-Naji.
BitClout, the first application that was created by AI-Naji and his team on the DeSo blockchain, had initially drawn controversy, as some found that they had profiles on the platform without their consent, while the application’s users were buying and selling tokens representing their identities. Such tokens are called “creator coins.”
AI-Naji responded to the controversy saying that DeSo now supports more than 200 social-media applications including Bitclout. “I think that if you don’t like those features, you now have the freedom to use any app you want. Some apps don’t have that functionality at all.”
But Before I get to the “selling monkeys to morons” quote,
I want to talk about
THE GOOD, THE BAD, AND THE UGLY
THE GOOD
My foray into Science 2.0 and then pondering what the movement into a Science 3.0 led me to an article by Dr. Vladimir Teif, who studies gene regulation and the nucleosome, as well as creating a worldwide group of scientists who discuss matters on chromatin and gene regulation in a journal club type format.
Fragile Nucleosome is an international community of scientists interested in chromatin and gene regulation. Fragile Nucleosome is active in several spaces: one is the Discord server where several hundred scientists chat informally on scientific matters. You can join the Fragile Nucleosome Discord server. Another activity of the group is the organization of weekly virtual seminars on Zoom. Our webinars are usually conducted on Wednesdays 9am Pacific time (5pm UK, 6pm Central Europe). Most previous seminars have been recorded and can be viewed at our YouTube channel. The schedule of upcoming webinars is shown below. Our third activity is the organization of weekly journal clubs detailed at a separate page (Fragile Nucleosome Journal Club).
This concept of science 3.0 he had coined back in 2009. As Dr Teif had mentioned
So essentially I first introduced this word Science 3.0 in 2009, and since then we did a lot to implement this in practice. The Twitter account @generegulation is also one of examples
This is curious as we still have an ill defined concept of what #science3_0 would look like but it is a good read nonetheless.
The concept of Science 2.0 was introduced almost a decade ago to describe the new generation of online-based tools for researchers allowing easier data sharing, collaboration and publishing. Although technically sound, the concept still does not work as expected. Here we provide a systematic line of arguments to modify the concept of Science 2.0, making it more consistent with the spirit and traditions of science and Internet. Our first correction to the Science 2.0 paradigm concerns the open-access publication models charging fees to the authors. As discussed elsewhere, we show that the monopoly of such publishing models increases biases and inequalities in the representation of scientific ideas based on the author’s income. Our second correction concerns post-publication comments online, which are all essentially non-anonymous in the current Science 2.0 paradigm. We conclude that scientific post-publication discussions require special anonymization systems. We further analyze the reasons of the failure of the current post-publication peer-review models and suggest what needs to be changed in Science 3.0 to convert Internet into a large journal club. [bold face added]
In this paper it is important to note the transition of a science 1.0, which involved hard copy journal publications usually only accessible in libraries to a more digital 2.0 format where data, papers, and ideas could be easily shared among networks of scientists.
As Dr. Teif states, the term “Science 2.0” had been coined back in 2009, and several influential journals including Science, Nature and Scientific American endorsed this term and suggested scientists to move online and their discussions online. However, even at present there are thousands on this science 2.0 platform, Dr Teif notes the number of scientists subscribed to many Science 2.0 networking groups such as on LinkedIn and ResearchGate have seemingly saturated over the years, with little new members in recent times.
The consensus is that science 2.0 networking is:
good because it multiplies the efforts of many scientists, including experts and adds to the scientific discourse unavailable on a 1.0 format
that online data sharing is good because it assists in the process of discovery (can see this evident with preprint servers, bio-curated databases, Github projects)
open-access publishing is beneficial because free access to professional articles and open-access will be the only publishing format in the future (although this is highly debatable as many journals are holding on to a type of “hybrid open access format” which is not truly open access
only sharing of unfinished works and critiques or opinions is good because it creates visibility for scientists where they can receive credit for their expert commentary
There are a few concerns on Science 3.0 Dr. Teif articulates:
A. Science 3.0 Still Needs Peer Review
Peer review of scientific findings will always be an imperative in the dissemination of well-done, properly controlled scientific discovery. As Science 2.0 relies on an army of scientific volunteers, the peer review process also involves an army of scientific experts who give their time to safeguard the credibility of science, by ensuring that findings are reliable and data is presented fairly and properly. It has been very evident, in this time of pandemic and the rapid increase of volumes of preprint server papers on Sars-COV2, that peer review is critical. Many of these papers on such preprint servers were later either retracted or failed a stringent peer review process.
Now many journals of the 1.0 format do not generally reward their peer reviewers other than the self credit that researchers use on their curriculum vitaes. Some journals, like the MDPI journal family, do issues peer reviewer credits which can be used to defray the high publication costs of open access (one area that many scientists lament about the open access movement; where the burden of publication cost lies on the individual researcher).
An issue which is highlighted is the potential for INFORMATION NOISE regarding the ability to self publish on Science 2.0 platforms.
The NEW BREED was born in 4/2012
An ongoing effort on this platform, https://pharmaceuticalintelligence.com/, is to establish a scientific methodology for curating scientific findings where one the goals is to assist to quell the information noise that can result from the massive amounts of new informatics and data occurring in the biomedical literature.
B. Open Access Publishing Model leads to biases and inequalities in the idea selection
The open access publishing model has been compared to the model applied by the advertising industry years ago and publishers then considered the journal articles as “advertisements”. However NOTHING could be further from the truth. In advertising the publishers claim the companies not the consumer pays for the ads. However in scientific open access publishing, although the consumer (libraries) do not pay for access the burden of BOTH the cost of doing the research and publishing the findings is now put on the individual researcher. Some of these publishing costs can be as high as $4000 USD per article, which is very high for most researchers. However many universities try to refund the publishers if they do open access publishing so it still costs the consumer and the individual researcher, limiting the cost savings to either.
However, this sets up a situation in which young researchers, who in general are not well funded, are struggling with the publication costs, and this sets up a bias or inequitable system which rewards the well funded older researchers and bigger academic labs.
C. Post publication comments and discussion require online hubs and anonymization systems
Many recent publications stress the importance of a post-publication review process or system yet, although many big journals like Nature and Science have their own blogs and commentary systems, these are rarely used. In fact they show that there are just 1 comment per 100 views of a journal article on these systems. In the traditional journals editors are the referees of comments and have the ability to censure comments or discourse. The article laments that comments should be easy to do on journals, like how easy it is to make comments on other social sites, however scientists are not offering their comments or opinions on the matter.
In a personal experience,
a well written commentary goes through editors which usually reject a comment like they were rejecting an original research article. Thus many scientists, I believe, after fashioning a well researched and referenced reply, do not get the light of day if not in the editor’s interests.
Therefore the need for anonymity is greatly needed and the lack of this may be the hindrance why scientific discourse is so limited on these types of Science 2.0 platforms. Platforms that have success in this arena include anonymous platforms like Wikipedia or certain closed LinkedIn professional platforms but more open platforms like Google Knowledge has been a failure.
A great example on this platform was a very spirited conversation on LinkedIn on genomics, tumor heterogeneity and personalized medicine which we curated from the LinkedIn discussion (unfortunately LinkedIn has closed many groups) seen here:
In this discussion, it was surprising that over a weekend so many scientists from all over the world contributed to a great discussion on the topic of tumor heterogeneity.
But many feel such discussions would be safer if they were anonymized. However then researchers do not get any credit for their opinions or commentaries.
A Major problem is how to take the intangible and make them into tangible assets which would both promote the discourse as well as reward those who take their time to improve scientific discussion.
This is where something like NFTs or a decentralized network may become important!
Below is an online @TwitterSpace Discussion we had with some young scientists who are just starting out and gave their thoughts on what SCIENCE 3.0 and the future of dissemination of science might look like, in light of this new Meta Verse. However we have to define each of these terms in light of Science and not just the Internet as merely a decentralized marketplace for commonly held goods.
This online discussion was tweeted out and got a fair amount of impressions (60) as well as interactors (50).
To introduce this discussion first a few startoff material which will fram this discourse
The Intenet and the Web is rapidly adopting a new “Web 3.0” format, with decentralized networks, enhanced virtual experiences, and greater interconnection between people. Here we start the discussion what will the move from Science 2.0, where dissemination of scientific findings was revolutionized and piggybacking on Web 2.0 or social media, to a Science 3.0 format. And what will it involve or what paradigms will be turned upside down?
Old Science 1.0 is still the backbone of all scientific discourse, built on the massive amount of experimental and review literature. However this literature was in analog format, and we moved to a more accesible digital open access format for both publications as well as raw data. However as there was a structure for 1.0, like the Dewey decimal system and indexing, 2.0 made science more accesible and easier to search due to the newer digital formats. Yet both needed an organizing structure; for 1.0 that was the scientific method of data and literature organization with libraries as the indexers. In 2.0 this relied on an army mostly of volunteers who did not have much in the way of incentivization to co-curate and organize the findings and massive literature.
Each version of Science has their caveats: their benefits as well as deficiencies. This curation and the ongoing discussion is meant to solidy the basis for the new format, along with definitions and determination of structure.
We had high hopes for Science 2.0, in particular the smashing of data and knowledge silos. However the digital age along with 2.0 platforms seemed to excaccerbate this somehow. We still are critically short on analysis!
We really need people and organizations to get on top of this new Web 3.0 or metaverse so the similar issues do not get in the way: namely we need to create an organizing structure (maybe as knowledgebases), we need INCENTIVIZED co-curators, and we need ANALYSIS… lots of it!!
Are these new technologies the cure or is it just another headache?
There were a few overarching themes whether one was talking about AI, NLP, Virtual Reality, or other new technologies with respect to this new meta verse and a concensus of Decentralized, Incentivized, and Integrated was commonly expressed among the attendees
The Following are some slides from representative Presentations
Other article of note on this topic on this Open Access Scientific Journal Include:
Medical Startups – Artificial Intelligence (AI) Startups in Healthcare
Reporters: Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN and Shraga Rottem, MD, DSc,
The motivation for this post is two fold:
First, we are presenting an application of AI, NLP, DL to our own medical text in the Genomics space. Here we present the first section of Part 1 in the following book. Part 1 has six subsections that yielded 12 plots. The entire Book is represented by 38 x 2 = 76 plots.
Second, we bring to the attention of the e-Reader the list of 276 Medical Startups – Artificial Intelligence (AI) Startups in Healthcare as a hot universe of R&D activity in Human Health.
Third, to highlight one academic center with an AI focus
Dear friends of the ETH AI Center,
We would like to provide you with some exciting updates from the ETH AI Center and its growing community.
As the Covid-19 restrictions in Switzerland have recently been lifted, we would like to hear from you what kind of events you would like to see in 2022! Participate in the survey to suggest event formats and topics that you would enjoy being a part of. We are already excited to learn what we can achieve together this year.
We already have many interesting events coming up, we look forward to seeing you at our main and community events!
LPBI Group is applying AI for Medical Text Analysis with Machine Learning and Natural Language Processing: Statistical and Deep Learning
Our Book
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
Medical Text Analysis of this Books shows the following results obtained by Madison Davis by applying Wolfram NLP for Biological Languages on our own Text. See below an Example:
With the explosive development of decentralized finance, we witness a phenomenal growth in tokenization of all kinds of assets, including equity, funds, debt, and real estate. By taking advantage of blockchain technology, digital assets are broadly grouped into fungible and non-fungible tokens (NFT). Here non-fungible tokens refer to those with unique and non-substitutable properties. NFT has widely attracted attention, and its protocols, standards, and applications are developing exponentially. It has been successfully applied to digital fantasy artwork, games, collectibles, etc. However, there is a lack of research in utilizing NFT in issues such as Intellectual Property. Applying for a patent and trademark is not only a time-consuming and lengthy process but also costly. NFT has considerable potential in the intellectual property domain. It can promote transparency and liquidity and open the market to innovators who aim to commercialize their inventions efficiently. The main objective of this paper is to examine the requirements of presenting intellectual property assets, specifically patents, as NFTs. Hence, we offer a layered conceptual NFT-based patent framework. Furthermore, a series of open challenges about NFT-based patents and the possible future directions are highlighted. The proposed framework provides fundamental elements and guidance for businesses in taking advantage of NFTs in real-world problems such as grant patents, funding, biotechnology, and so forth.
Introduction
Distributed ledger technologies (DLTs) such as blockchain are emerging technologies posing a threat to existing business models. Traditionally, most companies used centralized authorities in various aspects of their business, such as financial operations and setting up a trust with their counterparts. By the emergence of blockchain, centralized organizations can be substituted with a decentralized group of resources and actors. The blockchain mechanism was introduced in Bitcoin white paper in 2008, which lets users generate transactions and spend their money without the intervention of banks1. Ethereum, which is a second generation of blockchain, was introduced in 2014, allowing developers to run smart contracts on a distributed ledger. With smart contracts, developers and businesses can create financial applications that use cryptocurrencies and other forms of tokens for applications such as decentralized finance (DeFi), crowdfunding, decentralized exchanges, data records keeping, etc.2. Recent advances in distributed ledger technology have developed concepts that lead to cost reduction and the simplification of value exchange. Nowadays, by leveraging the advantages of blockchain and taking into account the governance issues, digital assets could be represented as tokens that existed in the blockchain network, which facilitates their transmission and traceability, increases their transparency, and improves their security3.
In the landscape of blockchain technology, there could be defined two types of tokens, including fungible tokens, in which all the tokens have equal value and non-fungible tokens (NFTs) that feature unique characteristics and are not interchangeable. Actually, non-fungible tokens are digital assets with a unique identifier that is stored on a blockchain4. NFT was initially suggested in Ethereum Improvement Proposals (EIP)-7215, and it was later expanded in EIP-11556. NFTs became one of the most widespread applications of blockchain technology that reached worldwide attention in early 2021. They can be digital representations of real-world objects. NFTs are tradable rights of digital assets (pictures, music, films, and virtual creations) where ownership is recorded in blockchain smart contracts7.
In particular, fungibility is the ability to exchange one with another of the same kind as an essential currency feature. The non-fungible token is unique and therefore cannot be substituted8. Recently, blockchain enthusiasts have indicated significant interest in various types of NFTs. They enthusiastically participate in NFT-related games or trades. CryptoPunks9, as one of the first NFTs on Ethereum, has developed almost 10,000 collectible punks and helped popularize the ERC-721 Standard. With the gamification of the breeding mechanics, CryptoKitties10 officially placed NFTs at the forefront of the market in 2017. CryptoKitties is an early blockchain game that enables users to buy, sell, collect, and digital breed cats. Another example is NBA Top Shot11, an NFT trading platform for digital short films buying and selling NBA events.
NFTs are developing remarkably and have provided many applications such as artist royalties, in-game assets, educational certificates, etc. However, it is a relatively new concept, and many areas of application need to be explored. Intellectual Property, including patent, trademark, and copyright, is an important area where NFTs can be applied usefully and solve existing problems.
Although NFTs have had many applications so far, it rarely has been used to solve real-world problems. In fact, an NFT is an exciting concept about Intellectual Property (IP). Applying for a patent and trademark is a time-consuming and lengthy process, but it is also costly. That is, registering a copyright or trademark may take months, while securing a patent can take years. On the contrary, with the help of unique features of NFT technology, it is possible to accelerate this process with considerable confidence and assurance about protecting the ownership of an IP. NFTs can offer IP protection while an applicant waits for the government to grant his/her more formal protection. It is cause for excitement that people who believe NFTs and Blockchain would make buying and selling patents easier, offering new opportunities for companies, universities, and inventors to make money off their innovations12. Patent holders will benefit from such innovation. It would give them the ability to ‘tokenize’ their patents. Because every transaction would be logged on a blockchain, it will be much easier to trace patent ownership changes. However, NFT would also facilitate the revenue generation of patents by democratizing patent licensing via NFT. NFTs support the intellectual property market by embedding automatic royalty collecting methods inside inventors’ works, providing them with financial benefits anytime their innovation is licensed. For example, each inventor’s patent would be minted as an NFT, and these NFTs would be joined together to form a commercial IP portfolio and minted as a compounded NFT. Each investor would automatically get their fair share of royalties whenever the licensing revenue is generated without tracking them down.
The authors in13, an overview of NFTs’ applications in different aspects such as gambling, games, and collectibles has been discussed. In addition4, provides a prototype for an event-tracking application based on Ethereum smart contract, and NFT as a solution for art and real estate auction systems is described in14. However, these studies have not discussed existing standards or a generalized architecture, enabling NFTs to be applied in diverse applications. For example, the authors in15 provide two general design patterns for creating and trading NFTs and discuss existing token standards for NFT. However, the proposed designs are limited to Ethereum, and other blockchains are not considered16. Moreover, different technologies for each step of the proposed procedure are not discussed. In8, the authors provide a conceptual framework for token designing and managing and discuss five views: token view, wallet view, transaction view, user interface view, and protocol view. However, no research provides a generalized conceptual framework for generating, recording, and tracing NFT based-IP, in blockchain network.
Even with the clear benefits that NFT-backed patents offer, there are a number of impediments to actually achieving such a system. For example, convincing patent owners to put current ownership records for their patents into NFTs poses an initial obstacle. Because there is no reliable framework for NFT-based patents, this paper provides a conceptual framework for presenting NFT-based patents with a comprehensive discussion on many aspects, ranging from the background, model components, token standards to application domains and research challenges. The main objective of this paper is to provide a layered conceptual NFT-based patent framework that can be used to register patents in a decentralized, tamper-proof, and trustworthy peer-to-peer network to trade and exchange them in the worldwide market. The main contributions of this paper are highlighted as follows:
Providing a comprehensive overview on tokenization of IP assets to create unique digital tokens.
Discussing the components of a distributed and trustworthy framework for minting NFT-based patents.
Highlighting a series of open challenges of NFT-based patents and enlightening the possible future trends.
The rest of the paper is structured as follows: “Background” section describes the Background of NFTs, Non-Fungible Token Standards. The NFT-based patent framework is described in “NFT-based patent framework” section. The Discussion and challenges are presented in “Discussion” section. Lastly, conclusions are given in “Conclusion” section.
Background
Colored Coins could be considered the first steps toward NFTs designed on the top of the Bitcoin network. Bitcoins are fungible, but it is possible to mark them to be distinguishable from the other bitcoins. These marked coins have special properties representing real-world assets like cars and stocks, and owners can prove their ownership of physical assets through the colored coins. By utilizing Colored Coins, users can transfer their marked coins’ ownership like a usual transaction and benefit from Bitcoin’s decentralized network17. Colored Coins had limited functionality due to the Bitcoin script limitations. Pepe is a green frog meme originated by Matt Furie that; users define tokens for Pepes and trade them through the Counterparty platform. Then, the tokens that were created by the picture of Pepes are decided if they are rare enough. Rare Pepe allows users to preserve scarcity, manage the ownership, and transfer their purchased Pepes.
In 2017, Larva Labs developed the first Ethereum-based NFT named CryptoPunks. It contains 10,000 unique human-like characters generated randomly. The official ownership of each character is stored in the Ethereum smart contract, and owners would trade characters. CryptoPunks project inspired CryptoKitties project. CryptoKitties attracts attention to NFT, and it is a pioneer in blockchain games and NFTs that launched in late 2017. CryptoKitties is a blockchain-based virtual game, and users collect and trade characters with unique features that shape kitties. This game was developed in Ethereum smart contract, and it pioneered the ERC-721 token, which was the first standard token in the Ethereum blockchain for NFTs. After the 2017 hype in NFTs, many projects started in this context. Due to increased attention to NFTs’ use-cases and growing market cap, different blockchains like EOS, Algorand, and Tezos started to support NFTs, and various marketplaces like SuperRare and Rarible, and OpenSea are developed to help users to trade NFTs. As mentioned, in general, assets are categorized into two main classes, fungible and non-fungible assets. Fungible assets are the ones that another similar asset can replace. Fungible items could have two main characteristics: replicability and divisibility.
Currency is a fungible item because a ten-dollar bill can be exchanged for another ten-dollar bill or divided into ten one-dollar bills. Despite fungible items, non-fungible items are unique and distinguishable. They cannot be divided or exchanged by another identical item. The first tweet on Twitter is a non-fungible item with mentioned characteristics. Another tweet cannot replace it, and it is unique and not divisible. NFT is a non-fungible cryptographic asset that is declared in a standard token format and has a unique set of attributes. Due to transparency, proof of ownership, and traceable transactions in the blockchain network, NFTs are created using blockchain technology.
Blockchain-based NFTs help enthusiasts create NFTs in the standard token format in blockchain, transfer the ownership of their NFTs to a buyer, assure uniqueness of NFTs, and manage NFTs completely. In addition, there are semi-fungible tokens that have characteristics of both fungible and non-fungible tokens. Semi-fungible tokens are fungible in the same class or specific time and non-fungible in other classes or different times. A plane ticket can be considered a semi-fungible token because a charter ticket can be exchanged by another charter ticket but cannot be exchanged by a first-class ticket. The concept of semi-fungible tokens plays the main role in blockchain-based games and reduces NFTs overhead. In Fig. 1, we illustrate fungible, non-fungible, and semi-fungible tokens. The main properties of NFTs are described as follows15:
Figure 1
Ownership: Because of the blockchain layer, the owner of NFT can easily prove the right of possession by his/her keys. Other nodes can verify the user’s ownership publicly.
Transferable: Users can freely transfer owned NFTs ownership to others on dedicated markets.
Transparency: By using blockchain, all transactions are transparent, and every node in the network can confirm and trace the trades.
Fraud Prevention: Fraud is one of the key problems in trading assets; hence, using NFTs ensures buyers buy a non-counterfeit item.
Immutability: Metadata, token ID, and history of transactions of NFTs are recorded in a distributed ledger, and it is impossible to change the information of the purchased NFTs.
Non-fungible standards
Ethereum blockchain was pioneered in implementing NFTs. ERC-721 token was the first standard token accepted in the Ethereum network. With the increase in popularity of the NFTs, developers started developing and enhancing NFTs standards in different blockchains like EOS, Algorand, and Tezos. This section provides a review of implemented NFTs standards on the mentioned blockchains.
Ethereum
ERC-721 was the first Standard for NFTs developed in Ethereum, a free and open-source standard. ERC-721 is an interface that a smart contract should implement to have the ability to transfer and manage NFTs. Each ERC-721 token has unique properties and a different Token Id. ERC-721 tokens include the owner’s information, a list of approved addresses, a transfer function that implements transferring tokens from owner to buyer, and other useful functions5.
In ERC-721, smart contracts can group tokens with the same configuration, and each token has different properties, so ERC-721 does not support fungible tokens. However, ERC-1155 is another standard on Ethereum developed by Enjin and has richer functionalities than ERC-721 that supports fungible, non-fungible, and semi-fungible tokens. In ERC-1155, IDs define the class of assets. So different IDs have a different class of assets, and each ID may contain different assets of the same class. Using ERC-1155, a user can transfer different types of tokens in a single transaction and mix multiple fungible and non-fungible types of tokens in a single smart contract6. ERC-721 and ERC-1155 both support operators in which the owner can let the operator originate transferring of the token.
EOSIO
EOSIO is an open-source blockchain platform released in 2018 and claims to eliminate transaction fees and increase transaction throughput. EOSIO differs from Ethereum in the wallet creation algorithm and procedure of handling transactions. dGood is a free standard developed in the EOS blockchain for assets, and it focuses on large-scale use cases. It supports a hierarchical naming structure in smart contracts. Each contract has a unique symbol and a list of categories, and each category contains a list of token names. Therefore, a single contract in dGoods could contain many tokens, which causes efficiency in transferring a group of tokens. Using this hierarchy, dGoods supports fungible, non-fungible, and semi-fungible tokens. It also supports batch transferring, where the owner can transfer many tokens in one operation18.
Algorand
Algorand is a new high-performance public blockchain launched in 2019. It provides scalability while maintaining security and decentralization. It supports smart contracts and tokens for representing assets19. Algorand defines Algorand Standard Assets (ASA) concept to create and manage assets in the Algorand blockchain. Using ASA, users are able to define fungible and non-fungible tokens. In Algorand, users can create NFTs or FTs without writing smart contracts, and they should run just a single transaction in the Algorand blockchain. Each transaction contains some mutable and immutable properties20.
Each account in Algorand can create up to 1000 assets, and for every asset, an account creates or receives, the minimum balance of the account increases by 0.1 Algos. Also, Algorand supports fractional NFTs by splitting an NFT into a group of divided FTs or NFTs, and each part can be exchanged dependently21. Algorand uses a Clawback Address that operates like an operator in ERC-1155, and it is allowed to transfer tokens of an owner who has permitted the operator.
Tezos
Tezos is another decentralized open-source blockchain. Tezos supports the meta-consensus concept. In addition to using a consensus protocol on the ledger’s state like Bitcoin and Ethereum, It also attempts to reach a consensus about how nodes and the protocol should change or upgrade22. FA2 (TZIP-12) is a standard for a unified token contract interface in the Tezos blockchain. FA2 supports different token types like fungible, non-fungible, and fractionalized NFT contracts. In Tezos, tokens are identified with a token contract address and token ID pair. Also, Tezos supports batch token transferring, which reduces the cost of transferring multiple tokens.
Flow
Flow was developed by Dapper Labs to remove the scalability limitation of the Ethereum blockchain. Flow is a fast and decentralized blockchain that focuses on games and digital collectibles. It improves throughput and scalability without sharding due to its architecture. Flow supports smart contracts using Cadence, which is a resource-oriented programming language. NFTs can be described as a resource with a unique id in Cadence. Resources have important rules for ownership management; that is, resources have just one owner and cannot be copied or lost. These features assure the NFT owner. NFTs’ metadata, including images and documents, can be stored off-chain or on-chain in Flow. In addition, Flow defines a Collection concept, in which each collection is an NFT resource that can include a list of resources. It is a dictionary that the key is resource id, and the value is corresponding NFT.
The collection concept provides batch transferring of NFTs. Besides, users can define an NFT for an FT. For instance, in CryptoKitties, a unique cat as an NFT can own a unique hat (another NFT). Flow uses Cadence’s second layer of access control to allow some operators to access some fields of the NFT23. In Table 1, we provide a comparison between explained standards. They are compared in support of fungible-tokens, non-fungible tokens, batch transferring that owner can transform multiple tokens in one operation, operator support in which the owner can approve an operator to originate token transfer, and fractionalized NFTs that an NFT can divide to different tokens and each exchange dependently.Table 1 Comparing NFT standards.
In this section, we propose a framework for presenting NFT-based patents. We describe details of the proposed distributed and trustworthy framework for minting NFT-based patents, as shown in Fig. 2. The proposed framework includes five main layers: Storage Layer, Authentication Layer, Verification Layer, Blockchain Layer, and Application Layer. Details of each layer and the general concepts are presented as follows.
Figure 2
Storage layer
The continuous rise of the data in blockchain technology is moving various information systems towards the use of decentralized storage networks. Decentralized storage networks were created to provide more benefits to the technological world24. Some of the benefits of using decentralized storage systems are explained: (1) Cost savings are achieved by making optimal use of current storage. (2) Multiple copies are kept on various nodes, avoiding bottlenecks on central servers and speeding up downloads. This foundation layer implicitly provides the infrastructure required for the storage. The items on NFT platforms have unique characteristics that must be included for identification.
Non-fungible token metadata provides information that describes a particular token ID. NFT metadata is either represented on the On-chain or Off-chain. On-chain means direct incorporation of the metadata into the NFT’s smart contract, which represents the tokens. On the other hand, off-chain storage means hosting the metadata separately25.
Blockchains provide decentralization but are expensive for data storage and never allow data to be removed. For example, because of the Ethereum blockchain’s current storage limits and high maintenance costs, many projects’ metadata is maintained off-chain. Developers utilize the ERC721 Standard, which features a method known as tokenURI. This method is implemented to let applications know the location of the metadata for a specific item. Currently, there are three solutions for off-chain storage, including InterPlanetary File System (IPFS), Pinata, and Filecoin.
IPFS
InterPlanetary File System (IPFS) is a peer-to-peer hypermedia protocol for decentralized media content storage. Because of the high cost of storing media files related to NFTS on Blockchain, IPFS can be the most affordable and efficient solution. IPFS combines multiple technologies inspired by Gita and BitTorrent, such as Block Exchange System, Distributed Hash Tables (DHT), and Version Control System26. On a peer-to-peer network, DHT is used to coordinate and maintain metadata.
In other words, the hash values must be mapped to the objects they represent. An IPFS generates a hash value that starts with the prefix {Q}_{m} and acts as a reference to a specific item when storing an object like a file. Objects larger than 256 KB are divided into smaller blocks up to 256 KB. Then a hash tree is used to interconnect all the blocks that are a part of the same object. IPFS uses Kamdelia DHT. The Block Exchange System, or BitSwap, is a BitTorrent-inspired system that is used to exchange blocks. It is possible to use asymmetric encryption to prevent unauthorized access to stored content on IPFS27.
Pinata
Pinata is a popular platform for managing and uploading files on IPFS. It provides secure and verifiable files for NFTs. Most data is stored off-chain by most NFTs, where a URL of the data is pointed to the NFT on the blockchain. The main problem here is that some information in the URL can change.
This indicates that an NFT supposed to describe a certain patent can be changed without anyone knowing. This defeats the purpose of the NFT in the first place. This is where Pinata comes in handy. Pinata uses the IPFS to create content-addressable hashes of data, also known as Content-Identifiers (CIDs). These CIDs serve as both a way of retrieving data and a means to ensure data validity. Those looking to retrieve data simply ask the IPFS network for the data associated with a certain CID, and if any node on the network contains that data, it will be returned to the requester. The data is automatically rehashed on the requester’s computer when the requester retrieves it to make sure that the data matches back up with the original CID they asked for. This process ensures the data that’s received is exactly what was asked for; if a malicious node attempts to send fake data, the resulting CID on the requester’s end will be different, alerting the requester that they’re receiving incorrect data28.
Filecoin
Another decentralized storage network is Filecoin. It is built on top of IPFS and is designed to store the most important data, such as media files. Truffle Suite has also launched NFT Development Template with Filecoin Box. NFT.Storage (Free Decentralized Storage for NFTs)29 allows users to easily and securely store their NFT content and metadata using IPFS and Filecoin. NFT.Storage is a service backed by Protocol Labs and Pinata specifically for storing NFT data. Through content addressing and decentralized storage, NFT.Storage allows developers to protect their NFT assets and associated metadata, ensuring that all NFTs follow best practices to stay accessible for the long term. NFT.Storage makes it completely frictionless to mint NFTs following best practices through resilient persistence on IPFS and Filecoin. NFT.Storage allows developers to quickly, safely, and for free store NFT data on decentralized networks. Anyone can leverage the power of IPFS and Filecoin to ensure the persistence of their NFTs. The details of this system are stated as follows30:
Content addressing
Once users upload data on NFT.Storage, They receive a CID, which is an IPFS hash of the content. CIDs are the data’s unique fingerprints, universal addresses that can be used to refer to it regardless of how or where it is stored. Using CIDs to reference NFT data avoids problems such as weak links and “rug pulls” since CIDs are generated from the content itself.
Provable storage
NFT.Storage uses Filecoin for long-term decentralized data storage. Filecoin uses cryptographic proofs to assure the NFT data’s durability and persistence over time.
Resilient retrieval
This data stored via IPFS and Filecoin can be fetched directly in the browser via any public IPFS.
Authentication Layer
The second layer is the authentication layer, which we briefly highlight its functions in this section. The Decentralized Identity (DID) approach assists users in collecting credentials from a variety of issuers, such as the government, educational institutions, or employers, and saving them in a digital wallet. The verifier then uses these credentials to verify a person’s validity by using a blockchain-based ledger to follow the “identity and access management (IAM)” process. Therefore, DID allows users to be in control of their identity. A lack of NFT verifiability also causes intellectual property and copyright infringements; of course, the chain of custody may be traced back to the creator’s public address to check whether a similar patent is filed using that address. However, there is no quick and foolproof way to check an NFTs creator’s legitimacy. Without such verification built into the NFT, an NFT proves ownership only over that NFT itself and nothing more.
Self-sovereign identity (SSI)31 is a solution to this problem. SSI is a new series of standards that will guide a new identity architecture for the Internet. With a focus on privacy, security interoperability, SSI applications use public-key cryptography with public blockchains to generate persistent identities for people with private and selective information disclosure. Blockchain technology offers a solution to establish trust and transparency and provide a secure and publicly verifiable KYC (Know Your Customer). The blockchain architecture allows you to collect information from various service providers into a single cryptographically secure and unchanging database that does not need a third party to verify the authenticity of the information.
The proposed platform generates patents-related smart contracts acting as a program that runs on the blockchain to receive and send transactions. They are unalterable privately identifying clients with a thorough KYC process. After KYC approval, then mint an NFT on the blockchain as a certificate of verification32. This article uses a decentralized authentication solution at this layer for authentication. This solution has been used for various applications in the field of the blockchain (exp: smart city, Internet of Things, etc.33, 34, but we use it here for the proposed framework (patent as NFTs). Details of this solution will be presented in the following.
Decentralized authentication
This section presents the authentication layer similar35 to build validated communication in a secure and decentralized manner via blockchain technology. As shown in Fig. 3, the authentication protocol comprises two processes, including registration and login.
Figure 3
Registration
In the registration process of a suggested authentication protocol, we first initialize a user’s public key as their identity key (UserName). Then, we upload this identity key on a blockchain, in which transactions can be verified later by other users. Finally, the user generates an identity transaction.
Login
After registration, a user logs in to the system. The login process is described as follows:
1. The user commits identity information and imports their secret key into the service application to log in.
2. A user who needs to log in sends a login request to the network’s service provider.
3. The service provider analyzes the login request, extracts the hash, queries the blockchain, and obtains identity information from an identity list (identity transactions).
4. The service provider responds with an authentication request when the above process is completed. A timestamp (to avoid a replay attack), the user’s UserName, and a signature are all included in the authentication request.
5. The user creates a signature with five parameters: timestamp, UserName, and PK, as well as the UserName and PK of the service provider. The user authentication credential is used as the signature.
6. The service provider verifies the received information, and if the received information is valid, the authentication succeeds; otherwise, the authentication fails, and the user’s login is denied.
The World Intellectual Property Organization (WIPO) and multiple target patent offices in various nations or regions should assess a patent application, resulting in inefficiency, high costs, and uncertainty. This study presented a conceptual NFT-based patent framework for issuing, validating, and sharing patent certificates. The platform aims to support counterfeit protection as well as secure access and management of certificates according to the needs of learners, companies, education institutions, and certification authorities.
Here, the certification authority (CA) is used to authenticate patent offices. The procedure will first validate a patent if it is provided with a digital certificate that meets the X.509 standard. Certificate authorities are introduced into the system to authenticate both the nodes and clients connected to the blockchain network.
Verification layer
In permissioned blockchains, just identified nodes can read and write in the distributed ledger. Nodes can act in different roles and have various permissions. Therefore, a distributed system can be designed to be the identified nodes for patent granting offices. Here the system is described conceptually at a high level. Figure 4 illustrates the sequence diagram of this layer. This layer includes four levels as below:
Figure 4
Digitalization
For a patent to publish as an NFT in the blockchain, it must have a digitalized format. This level is the “filling step” in traditional patent registering. An application could be designed in the application layer to allow users to enter different patent information online.
Recording
Patents provide valuable information and would bring financial benefits for their owner. If they are publicly published in a blockchain network, miners may refuse the patent and take the innovation for themselves. At least it can weaken consensus reliability and encourage miners to misbehave. The inventor should record his innovation privately first using proof of existence to prevent this. The inventor generates the hash of the patent document and records it in the blockchain. As soon as it is recorded in the blockchain, the timestamp and the hash are available for others publicly. Then, the inventor can prove the existence of the patent document whenever it is needed.
Furthermore, using methods like Decision Thinking36, an inventor can record each phase of patent development separately. In each stage, a user generates the hash of the finished part and publishes the hash regarding the last part’s hash. Finally, they have a coupled series of hashes that indicate patent development, and they can prove the existence of each phase using the original related documents. This level should be done to prevent others from abusing the patent and taking it for themselves. The inventor can make sure that their patent document is recorded confidentially and immutably37.
Different hash algorithms exist with different architecture, time complexity, and security considerations. Hash functions should satisfy two main requirements: Pre-Image Resistance: This means that it should be computationally hard to find the input of a hash function while the output and the hash algorithm are known publicly. Collision Resistance: This means that it is computationally hard to find two arbitrary inputs, x, and y, that have the same hash output. These requirements are vital for recording patents. First, the hash function should be Pre-Image Resistance to make it impossible for others to calculate the patent documentation. Otherwise, everybody can read the patent, even before its official publication. Second, the hash function should satisfy Collision Resistance to preclude users from changing their document after recording. Otherwise, users can upload another document, and after a while, they can replace it with another one.
There are various hash algorithms, and MD and SHA families are the most useful algorithms. According to38, Collisions have been found for MD2, MD4, MD5, SHA-0, and SHA-1 hash functions. Hence, they cannot be a good choice for recording patents. SHA2 hash algorithm is secure, and no collision has been found. Although SHA2 is noticeably slower than prior hash algorithms, the recording phase is not highly time-sensitive. So, it is a better choice and provides excellent security for users.
Validating
In this phase, the inventors first create NFT for their patents and publish it to the miners/validators. Miners are some identified nodes that validate NFTs to record in the blockchain. Due to the specialization of the patent validation, miners cannot be inexpert public persons. In addition, patent offices are not too many to make the network fully decentralized. Therefore, the miners can be related specialist persons that are certified by the patent offices. They should receive a digital certificate from patent offices that show their eligibility to referee a patent.
Digital certificate
Digital certificates are digital credentials used to verify networked entities’ online identities. They usually include a public key as well as the owner’s identification. They are issued by Certification Authorities (CAs), who must verify the certificate holder’s identity. Certificates contain cryptographic keys for signing, encryption, and decryption. X.509 is a standard that defines the format of public-key certificates and is signed by a certificate authority. X.509 standard has multiple fields, and its structure is shown in Fig. 5. Version: This field indicated the version of the X.509 standard. X.509 contains multiple versions, and each version has a different structure. According to the CA, validators can choose their desired version. Serial Number: It is used to distinguish a certificate from other certificates. Thus, each certificate has a unique serial number. Signature Algorithm Identifier: This field indicates the cryptographic encryption algorithm used by a certificate authority. Issuer Name: This field indicates the issuer’s name, which is generally certificate authority. Validity Period: Each certificate is valid for a defined period, defined as the Validity Period. This limited period partly protects certificates against exposing CA’s private key. Subject Name: Name of the requester. In our proposed framework, it is the validator’s name. Subject Public Key Info: Shows the CA’s or organization’s public key that issued the certificate. These fields are identical among all versions of the X.509 standard39.
Figure 5
Certificate authority
A Certificate Authority (CA) issues digital certificates. CAs encrypt the certificate with their private key, which is not public, and others can decrypt the certificates containing the CA’s public key.
Here, the patent office creates a certificate for requested patent referees. The patent office writes the information of the validator in their certificate and encrypts it with the patent offices’ private key. The validator can use the certificate to assure others about their eligibility. Other nodes can check the requesting node’s information by decrypting the certificate using the public key of the patent office. Therefore, persons can join the network’s miners/validators using their credentials. In this phase, miners perform Formal Examinations, Prior Art Research, and Substantive Examinations and vote to grant or refuse the patent.
Miners perform a consensus about the patent and record the patent in the blockchain. After that, the NFT is recorded in the blockchain with corresponding comments in granting or needing reformations. If the miners detect the NFT as a malicious request, they do not record it in the blockchain.
Blockchain layer
This layer plays as a middleware between the Verification Layer and Application Layer in the patents as NFTs architecture. The main purpose of the blockchain layer in the proposed architecture is to provide IP management. We find that transitioning to a blockchain-based patent as a NFTs records system enables many previously suggested improvements to current patent systems in a flexible, scalable, and transparent manner.
On the other hand, we can use multiple blockchain platforms, including Ethereum, EOS, Flow, and Tezos. Blockchain Systems can be mainly classified into two major types: Permissionless (public) and Permissioned (private) Blockchains based on their consensus mechanism. In a public blockchain, any node can participate in the peer-to-peer network, where the blockchain is fully decentralized. A node can leave the network without any consent from the other nodes in the network.
Bitcoin is one of the most popular examples that fall under the public and permissionless blockchain. Proof of Work (POW), Proof-of-Stake (POS), and directed acyclic graph (DAG) are some examples of consensus algorithms in permissionless blockchains. Bitcoin and Ethereum, two famous and trustable blockchain networks, use the PoW consensus mechanism. Blockchain platforms like Cardano and EOS adopt the PoS consensus40.
Nodes require specific access or permission to get network authentication in a private blockchain. Hyperledger is among the most popular private blockchains, which allow only permissioned members to join the network after authentication. This provides security to a group of entities that do not completely trust one another but wants to achieve a common objective such as exchanging information. All entities of a permissioned blockchain network can use Byzantine-fault-tolerant (BFT) consensus. The Fabric has a membership identity service that manages user IDs and verifies network participants.
Therefore, members are aware of each other’s identity while maintaining privacy and secrecy because they are unaware of each other’s activities41. Due to their more secure nature, private blockchains have sparked a large interest in banking and financial organizations, believing that these platforms can disrupt current centralized systems. Hyperledger, Quorum, Corda, EOS are some examples of permissioned blockchains42.
Reaching consensus in a distributed environment is a challenge. Blockchain is a decentralized network with no central node to observe and check all transactions. Thus, there is a need to design protocols that indicate all transactions are valid. So, the consensus algorithms are considered as the core of each blockchain43. In distributed systems, the consensus has become a problem in which all network members (nodes) agree on accept or reject of a block. When all network members accept the new block, it can append to the previous block.
As mentioned, the main concern in the blockchains is how to reach consensus among network members. A wide range of consensus algorithms has been designed in which each of them has its own pros and cons42. Blockchain consensus algorithms are mainly classified into three groups shown in Table 2. As the first group, proof-based consensus algorithms require the nodes joining the verifying network to demonstrate their qualification to do the appending task. The second group is voting-based consensus that requires validators in the network to share their results of validating a new block or transaction before making the final decision. The third group is DAG-based consensus, a new class of consensus algorithms. These algorithms allow several different blocks to be published and recorded simultaneously on the network.Table 2 Consensus algorithms in blockchain networks.
The proposed patent as the NFTs platform that builds blockchain intellectual property empowers the entire patent ecosystem. It is a solution that removes barriers by addressing fundamental issues within the traditional patent ecosystem. Blockchain can efficiently handle patents and trademarks by effectively reducing approval wait time and other required resources. The user entities involved in Intellectual Property management are Creators, Patent Consumers, and Copyright Managing Entities. Users with ownership of the original data are the patent creators, e.g., inventors, writers, and researchers. Patent Consumers are the users who are willing to consume the content and support the creator’s work. On the other hand, Users responsible for protecting the creators’ Intellectual Property are the copyright management entities, e.g., lawyers. The patents as NFTs solution for IP management in blockchain layer works by implementing the following steps62:
Creators sign up to the platform
Creators need to sign up on the blockchain platform to patent their creative work. The identity information will be required while signing up.
Creators upload IP on the blockchain network
Now, add an intellectual property for which the patent application is required. The creator will upload the information related to IP and the data on the blockchain network. Blockchain ensures traceability and auditability to prevent data from duplicity and manipulation. The patent becomes visible to all network members once it is uploaded to the blockchain.
Consumers generate request to use the content
Consumers who want to access the content must first register on the blockchain network. After Signing up, consumers can ask creators to grant access to the patented content. Before the patent owner authorizes the request, a Smart Contract is created to allow customers to access information such as the owner’s data. Furthermore, consumers are required to pay fees in either fiat money or unique tokens in order to use the creator’s original information. When the creator approves the request, an NDA (Non-Disclosure Agreement) is produced and signed by both parties. Blockchain manages the agreement and guarantees that all parties agree to the terms and conditions filed.
Patent management entities leverage blockchain to protect copyrights and solve related disputes
Blockchain assists the patent management entities in resolving a variety of disputes that may include: sharing confidential information, establishing proof of authorship, transferring IP rights, and making defensive publications, etc. Suppose a person used an Invention from a patent for his company without the inventor’s consent. The inventor can report it to the patent office and claim that he is the owner of that invention.
Application layer
The patent Platform Global Marketplace technology would allow many enterprises, governments, universities, and Small and medium-sized enterprises (SMEs) worldwide to tokenize patents as NFTs to create an infrastructure for storing patent records on a blockchain-based network and developing a decentralized marketplace in which patent holders would easily sell or otherwise monetize their patents. The NFTs-based patent can use smart contracts to determine a set price for a license or purchase.
Any buyer satisfied with the conditions can pay and immediately unlock the rights to the patent without either party ever having to interact directly. While patents are currently regulated jurisdictionally around the world, a blockchain-based patent marketplace using NFTs can reduce the geographical barriers between patent systems using as simple a tool as a search query. The ease of access to patents globally can help aspiring inventors accelerate the innovative process by building upon others’ patented inventions through licenses. There are a wide variety of use cases for patent NFTs such as SMEs, Patent Organization, Grant & Funding, and fundraising/transferring information relating to patents. These applications keep growing as time progresses, and we are constantly finding new ways to utilize these tokens. Some of the most commonly used applications can be seen as follows.
SMEs
The aim is to move intellectual property assets onto a digital, centralized, and secure blockchain network, enabling easier commercialization of patents, especially for small or medium enterprises (SMEs). Smart contracts can be attached to NFTs so terms of use and ownership can be outlined and agreed upon without incurring as many legal fees as traditional IP transfers. This is believed to help SMEs secure funding, as they could more easily leverage the previously undisclosed value of their patent portfolios63.
Transfer ownership of patents
NFTs can be used to transfer ownership of patents. The blockchain can be used to keep track of patent owners, and tokens would include self-executing contracts that transfer the legal rights associated with patents when the tokens are transferred. A partnership between IBM and IPwe has spearheaded the use of NFTs to secure patent ownership. These two companies have teamed together to build the infrastructure for an NFT-based patent marketplace.
Discussion
There are exciting proposals in the legal and economic literature that suggest seemingly straightforward solutions to many of the issues plaguing current patent systems. However, most solutions would constitute major administrative disruptions and place significant and continuous financial burdens on patent offices or their users. An NFT-based patents system not only makes many of these ideas administratively feasible but can also be examined in a step-wise, scalable, and very public manner.
Furthermore, NFT-based patents may facilitate reliable information sharing among offices and patentees worldwide, reducing the burden on examiners and perhaps even accelerating harmonization efforts. NFT-based patents also have additional transparency and archival attributes baked in. A patent should be a privilege bestowed on those who take resource-intensive risks to explore the frontier of technological capabilities. As a reward for their achievements, full transparency of these rewards is much public interest. It is a society that pays for administrative and economic inefficiencies that exist in today’s systems. NFT-based patents can enhance this transparency. From an organizational perspective, an NFT-based patent can remove current bottlenecks in patent processes by making these processes more efficient, rapid, and convenient for applicants without compromising the quality of granted patents.
The proposed framework encounters some challenges that should be solved to reach a developed patent verification platform. First, technical problems are discussed. The consensus method that is used in the verification layer is not addressed in detail. Due to the permissioned structure of miners in the NFT-based patents, consensus algorithms like PBFT, Federated Consensus, and Round Robin Consensus are designed for permissioned blockchains can be applied. Also, miners/validators spend some time validating the patents; hence a protocol should be designed to profit them. Some challenges like proving the miners’ time and effort, the price that inventors should pay to miners, and other economic trade-offs should be considered.
Different NFT standards were discussed. If various patent services use NFT standards, there will be some cross-platform problems. For instance, transferring an NFT from Ethereum blockchain (ERC-721 token) to EOS blockchain is not a forward and straight work and needs some considerations. Also, people usually trade NFTs in marketplaces such as Rarible and OpenSea. These marketplaces are centralized and may prompt some challenges because of their centralized nature. Besides, there exist some other types of challenges. For example, the novelty of NFT-based patents and blockchain services.
Blockchain-based patent service has not been tested before. The patent registration procedure and concepts of the Patent as NFT system may be ambiguous for people who still prefer conventional centralized patent systems over decentralized ones. It should be noted that there are some problems in the mining part. Miners should receive certificates from the accepted organizations. Determining these organizations and how they accept referees as validators need more consideration. Some types of inventions in some countries are prohibited, and inventors cannot register them. In NFT-based patents, inventors can register their patents publicly, and maybe some collisions occur between inventors and the government. There exist some misunderstandings about NFT’s ownership rights. It is not clear that when a person buys an NFT, which rights are given to them exactly; for instance, they have property rights or have moral rights, too.
Conclusion
Blockchain technology provides strong timestamping, the potential for smart contracts, proof-of-existence. It enables creating a transparent, distributed, cost-effective, and resilient environment that is open to all and where each transaction is auditable. On the other hand, blockchain is a definite boon to the IP industry, benefitting patent owners. When blockchain technology’s intrinsic characteristics are applied to the IP domain, it helps copyrights. This paper provided a conceptual framework for presenting an NFT-based patent with a comprehensive discussion of many aspects: background, model components, token standards to application areas, and research challenges. The proposed framework includes five main layers: Storage Layer, Authentication Layer, Verification Layer, Blockchain Layer, and Application. The primary purpose of this patent framework was to provide an NFT-based concept that could be used to patent a decentralized, anti-tamper, and reliable network for trade and exchange around the world. Finally, we addressed several open challenges to NFT-based inventions.
References
Nakamoto, S. Bitcoin: A peer-to-peer electronic cash system. Decent. Bus. Rev. 21260, https://bitcoin.org/bitcoin.pdf (2008).
Buterin, V. A next-generation smart contract and decentralized application platform. White Pap.3 (2014).
Nofer, M., Gomber, P., Hinz, O. & Schiereck, D. Business & infomation system engineering. Blockchain59, 183–187 (2017).Google Scholar
Entriken, W., Shirley, D., Evans, J. & Sachs, N. EIP 721: ERC-721 non-fungible token standard. Ethereum Improv. Propos.. https://eips.ethereum.org/EIPS/eip-721 (2018).
Radomski, W. et al. Eip 1155: Erc-1155 multi token standard. In Ethereum, Standard (2018).
Fairfield, J. Tokenized: The law of non-fungible tokens and unique digital property. Indiana Law J. forthcoming (2021).
Chevet, S. Blockchain technology and non-fungible tokens: Reshaping value chains in creative industries. Available at SSRN 3212662 (2018).
Bal, M. & Ner, C. NFTracer: a Non-Fungible token tracking proof-of-concept using Hyperledger Fabric. arXiv preprint arXiv:1905.04795 (2019).
Wang, Q., Li, R., Wang, Q. & Chen, S. Non-fungible token (NFT): Overview, evaluation, opportunities and challenges. arXiv preprint arXiv:2105.07447 (2021).
Qu, Q., Nurgaliev, I., Muzammal, M., Jensen, C. S. & Fan, J. On spatio-temporal blockchain query processing. Future Gener. Comput. Syst.98: 208–218 (2019).ArticleGoogle Scholar
Rosenfeld, M. Overview of colored coins. White paper, bitcoil. co. il41, 94 (2012).
Benisi, N. Z., Aminian, M. & Javadi, B. Blockchain-based decentralized storage networks: A survey. J. Netw. Comput. Appl.162, 102656 (2020).ArticleGoogle Scholar
NFTReview. On-chain vs. Off-chain Metadata (2021).
Nizamuddin, N., Salah, K., Azad, M. A., Arshad, J. & Rehman, M. Decentralized document version control using ethereum blockchain and IPFS. Comput. Electr. Eng.76, 183–197 (2019).ArticleGoogle Scholar
Tut, K. Who Is Responsible for NFT Data? (2020).
nft.storage. Free Storage for NFTs, Retrieved 16 May, 2021, from https://nft.storage/. (2021).
Psaras, Y. & Dias, D. in 2020 50th Annual IEEE-IFIP International Conference on Dependable Systems and Networks-Supplemental Volume (DSN-S). 80–80 (IEEE).
Tanner, J. & Roelofs, C. NFTs and the need for Self-Sovereign Identity (2021).
Martens, D., Tuyll van Serooskerken, A. V. & Steenhagen, M. Exploring the potential of blockchain for KYC. J. Digit. Bank.2, 123–131 (2017).Google Scholar
Hammi, M. T., Bellot, P. & Serhrouchni, A. In 2018 IEEE Wireless Communications and Networking Conference (WCNC). 1–6 (IEEE).
Khalid, U. et al. A decentralized lightweight blockchain-based authentication mechanism for IoT systems. Cluster Comput. 1–21 (2020).
Zhong, Y. et al. Distributed blockchain-based authentication and authorization protocol for smart grid. Wirel. Commun. Mobile Comput. (2021).
Schönhals, A., Hepp, T. & Gipp, B. In Proceedings of the 1st Workshop on Cryptocurrencies and Blockchains for Distributed Systems. 105–110.
Verma, S. & Prajapati, G. A Survey of Cryptographic Hash Algorithms and Issues. International Journal of Computer Security & Source Code Analysis (IJCSSCA) 1, 17–20, (2015).
Verma, S. & Prajapati, G. A survey of cryptographic hash algorithms and issues. Int. J. Comput. Secur. Source Code Anal. (IJCSSCA)1 (2015).
SDK, I. X.509 Certificates (1996).
Helliar, C. V., Crawford, L., Rocca, L., Teodori, C. & Veneziani, M. Permissionless and permissioned blockchain diffusion. Int. J. Inf. Manag.54, 102136 (2020).ArticleGoogle Scholar
Frizzo-Barker, J. et al. Blockchain as a disruptive technology for business: A systematic review. Int. J. Inf. Manag.51, 102029 (2020).ArticleGoogle Scholar
Bamakan, S. M. H., Motavali, A. & Bondarti, A. B. A survey of blockchain consensus algorithms performance evaluation criteria. Expert Syst. Appl.154, 113385 (2020).ArticleGoogle Scholar
Bamakan, S. M. H., Bondarti, A. B., Bondarti, P. B. & Qu, Q. Blockchain technology forecasting by patent analytics and text mining. Blockchain Res. Appl. 100019 (2021).
Castro, M. & Liskov, B. Practical Byzantine fault tolerance and proactive recovery. ACM Trans. Comput. Syst. (TOCS)20, 398–461 (2002).ArticleGoogle Scholar
Muratov, F., Lebedev, A., Iushkevich, N., Nasrulin, B. & Takemiya, M. YAC: BFT consensus algorithm for blockchain. arXiv preprint arXiv:1809.00554 (2018).
Bessani, A., Sousa, J. & Alchieri, E. E. In 2014 44th Annual IEEE/IFIP International Conference on Dependable Systems and Networks. 355–362 (IEEE).
Todd, P. Ripple protocol consensus algorithm review. May 11th (2015).
Ongaro, D. & Ousterhout, J. In 2014 {USENIX} Annual Technical Conference ({USENIX}{ATC} 14). 305–319.
Dziembowski, S., Faust, S., Kolmogorov, V. & Pietrzak, K. In Annual Cryptology Conference. 585–605 (Springer).
Bentov, I., Lee, C., Mizrahi, A. & Rosenfeld, M. Proof of Activity: Extending Bitcoin’s Proof of Work via Proof of Stake. IACR Cryptology ePrint Archive2014, 452 (2014).Google Scholar
Bramas, Q. The Stability and the Security of the Tangle (2018).
Baird, L. The swirlds hashgraph consensus algorithm: Fair, fast, byzantine fault tolerance. In Swirlds Tech Reports SWIRLDS-TR-2016–01, Tech. Rep (2016).
LeMahieu, C. Nano: A feeless distributed cryptocurrency network. Nano [Online resource].https://nano.org/en/whitepaper (date of access: 24.03. 2018) 16, 17 (2018).
Casino, F., Dasaklis, T. K. & Patsakis, C. A systematic literature review of blockchain-based applications: Current status, classification and open issues. Telematics Inform.36, 55–81 (2019).ArticleGoogle Scholar
bigredawesomedodo. Helping Small Businesses Survive and Grow With Marketing, Retrieved 3 June, 2021, from https://bigredawesomedodo.com/nft/. (2020).
This work has been partially supported by CAS President’s International Fellowship Initiative, China [grant number 2021VTB0002, 2021] and National Natural Science Foundation of China (No. 61902385).
Author information
Affiliations
Department of Industrial Management, Yazd University, Yazd City, IranSeyed Mojtaba Hosseini Bamakan
Department of Electrical and Computer Engineering, Isfahan University of Technology, Isfahan City, IranNasim Nezhadsistani
School of Electrical and Computer Engineering, University of Tehran, Tehran City, IranOmid Bodaghi
Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, ChinaSeyed Mojtaba Hosseini Bamakan & Qiang Qu
From: Heidi Rheim et al. GA4GH: International policies and standards for data sharing across genomic research and healthcare. (2021): Cell Genomics, Volume 1 Issue 2.
Siloing genomic data in institutions/jurisdictions limits learning and knowledge
GA4GH policy frameworks enable responsible genomic data sharing
GA4GH technical standards ensure interoperability, broad access, and global benefits
Data sharing across research and healthcare will extend the potential of genomics
Summary
The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical and genomic data through both harmonized data aggregation and federated approaches. The decreasing cost of genomic sequencing (along with other genome-wide molecular assays) and increasing evidence of its clinical utility will soon drive the generation of sequence data from tens of millions of humans, with increasing levels of diversity. In this perspective, we present the GA4GH strategies for addressing the major challenges of this data revolution. We describe the GA4GH organization, which is fueled by the development efforts of eight Work Streams and informed by the needs of 24 Driver Projects and other key stakeholders. We present the GA4GH suite of secure, interoperable technical standards and policy frameworks and review the current status of standards, their relevance to key domains of research and clinical care, and future plans of GA4GH. Broad international participation in building, adopting, and deploying GA4GH standards and frameworks will catalyze an unprecedented effort in data sharing that will be critical to advancing genomic medicine and ensuring that all populations can access its benefits.
In order for genomic and personalized medicine to come to fruition it is imperative that data siloes around the world are broken down, allowing the international collaboration for the collection, storage, transferring, accessing and analying of molecular and health-related data.
We had talked on this site in numerous articles about the problems data siloes produce. By data siloes we are meaning that collection and storage of not only DATA but intellectual thought are being held behind physical, electronic, and intellectual walls and inacessible to other scientisits not belonging either to a particular institituion or even a collaborative network.
Standardization and harmonization of data is key to this effort to sharing electronic records. The EU has taken bold action in this matter. The following section is about the General Data Protection Regulation of the EU and can be found at the following link:
The data protection package adopted in May 2016 aims at making Europe fit for the digital age. More than 90% of Europeans say they want the same data protection rights across the EU and regardless of where their data is processed.
The General Data Protection Regulation (GDPR)
Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. This text includes the corrigendum published in the OJEU of 23 May 2018.
The regulation is an essential step to strengthen individuals’ fundamental rights in the digital age and facilitate business by clarifying rules for companies and public bodies in the digital single market. A single law will also do away with the current fragmentation in different national systems and unnecessary administrative burdens.
Directive (EU) 2016/680 on the protection of natural persons regarding processing of personal data connected with criminal offences or the execution of criminal penalties, and on the free movement of such data.
The directive protects citizens’ fundamental right to data protection whenever personal data is used by criminal law enforcement authorities for law enforcement purposes. It will in particular ensure that the personal data of victims, witnesses, and suspects of crime are duly protected and will facilitate cross-border cooperation in the fight against crime and terrorism.
The directive entered into force on 5 May 2016 and EU countries had to transpose it into their national law by 6 May 2018.
The following paper by the organiztion The Global Alliance for Genomics and Health discusses these types of collaborative efforts to break down data silos in personalized medicine. This organization has over 2000 subscribers in over 90 countries encompassing over 60 organizations.
Enabling responsible genomic data sharing for the benefit of human health
The Global Alliance for Genomics and Health (GA4GH) is a policy-framing and technical standards-setting organization, seeking to enable responsible genomic data sharing within a human rights framework.
he Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 600+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.
GA4GH Connect is a five-year strategic plan that aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022. GA4GH Connect links our Work Streams with Driver Projects—real-world genomic data initiatives that help guide our development efforts and pilot our tools.
The Global Alliance for Genomics and Health (GA4GH) is a worldwide alliance of genomics researchers, data scientists, healthcare practitioners, and other stakeholders. We are collaborating to establish policy frameworks and technical standards for responsible, international sharing of genomic and other molecular data as well as related health data. Founded in 2013,3 the GA4GH community now consists of more than 1,000 individuals across more than 90 countries working together to enable broad sharing that transcends the boundaries of any single institution or country (see https://www.ga4gh.org).In this perspective, we present the strategic goals of GA4GH and detail current strategies and operational approaches to enable responsible sharing of clinical and genomic data, through both harmonized data aggregation and federated approaches, to advance genomic medicine and research. We describe technical and policy development activities of the eight GA4GH Work Streams and implementation activities across 24 real-world genomic data initiatives (“Driver Projects”). We review how GA4GH is addressing the major areas in which genomics is currently deployed including rare disease, common disease, cancer, and infectious disease. Finally, we describe differences between genomic sequence data that are generated for research versus healthcare purposes, and define strategies for meeting the unique challenges of responsibly enabling access to data acquired in the clinical setting.
GA4GH organization
GA4GH has partnered with 24 real-world genomic data initiatives (Driver Projects) to ensure its standards are fit for purpose and driven by real-world needs. Driver Projects make a commitment to help guide GA4GH development efforts and pilot GA4GH standards (see Table 2). Each Driver Project is expected to dedicate at least two full-time equivalents to GA4GH standards development, which takes place in the context of GA4GH Work Streams (see Figure 1). Work Streams are the key production teams of GA4GH, tackling challenges in eight distinct areas across the data life cycle (see Box 1). Work Streams consist of experts from their respective sub-disciplines and include membership from Driver Projects as well as hundreds of other organizations across the international genomics and health community.
Figure 1Matrix structure of the Global Alliance for Genomics and HealthShow full caption
Box 1GA4GH Work Stream focus areasThe GA4GH Work Streams are the key production teams of the organization. Each tackles a specific area in the data life cycle, as described below (URLs listed in the web resources).
(1)Data use & researcher identities: Develops ontologies and data models to streamline global access to datasets generated in any country9,10
(2)Genomic knowledge standards: Develops specifications and data models for exchanging genomic variant observations and knowledge18
(3)Cloud: Develops federated analysis approaches to support the statistical rigor needed to learn from large datasets
(4)Data privacy & security: Develops guidelines and recommendations to ensure identifiable genomic and phenotypic data remain appropriately secure without sacrificing their analytic potential
(5)Regulatory & ethics: Develops policies and recommendations for ensuring individual-level data are interoperable with existing norms and follow core ethical principles
(6)Discovery: Develops data models and APIs to make data findable, accessible, interoperable, and reusable (FAIR)
(7)Clinical & phenotypic data capture & exchange: Develops data models to ensure genomic data is most impactful through rich metadata collected in a standardized way
(8)Large-scale genomics: Develops APIs and file formats to ensure harmonized technological platforms can support large-scale computing
For more articles on Open Access, Science 2.0, and Data Networks for Genomics on this Open Access Scientific Journal see:
AI in Pharma: From Tool to Value Creator 🚀
Over the past 5 years, pharma’s AI footprint has expanded rapidly and the investment trends tell a clear story.
💡 ~60% of collaborations and acquisitions now focus on TargetDiscovery and Validation — pharma’s main frontier to shorten early-stage R&D timelines and boost success rates through PrecisionBiology.
⚗️ The second-largest area (~25%) centers on AI-driven DrugDesign and MoleculeOptimization, where algorithms accelerate CandidateSelection, refine molecular properties, and enable NewModalities such as Biologics and CellAndGeneTherapies.
🏆 Among top players, Eli Lilly and Company stands out as the most active investor — making AI a true StrategicCapability, not just another research tool.
The takeaway?
AI isn’t just supporting pharma anymore, it’s reshaping it.
Source: Bita Sehat, PhD, MBA
hashtag#ai hashtag#lifesciences hashtag#pharmaceuticals hashtag#techbio hashtag#biotech